Guidelines for the Diagnosis, Treatment and Prevention of Leprosy by Guidelines Development Group et al.
Guidelines for the 
Diagnosis, Treatment and 
Prevention of Leprosy
The Guidelines for the Diagnosis, Treatment and Prevention of Leprosy provide 
state-of-the-art knowledge and evidence on leprosy diagnosis, treatment and 
prevention based on a public health approach in endemic countries. The target 
audience of this document includes policy-makers in leprosy or infectious 
diseases in the ministries of health (especially but not limited to endemic 
countries), nongovernmental organizations, clinicians, pharmaceutical 
companies, donors and affected persons. These leprosy guidelines have been 
developed by strictly following WHO's GRADE approach wherein all available 
evidence published in English has been taken into consideration. Funding 
support was received from The Nippon Foundation. 
9 7 8 9 2 9 0 2 2 6 3 8 3
ISBN 978-92-9022-638-3
Guidelines for the diagnosis, treatment  
and prevention of leprosy
Guidelines for the diagnosis, treatment and prevention of leprosy
ISBN: 978 92 9022 638 3
© World Health Organization 2018
Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO 
licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). 
Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the 
work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses 
any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you 
must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you 
should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health 
Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall 
be the binding and authentic edition”. 
Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the 
World Intellectual Property Organization..
Suggested citation. Guidelines for the diagnosis, treatment and prevention of leprosy. New Delhi: World Health Organization, 
Regional Office for South-East Asia; 2017. Licence: CC BY-NC-SA 3.0 IGO.
Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for 
commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. 
Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or 
images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the 
copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely 
with the user.
General disclaimers. The designations employed and the presentation of the material in this publication do not 
imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, 
territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted 
and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. 
The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or 
recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, 
the names of proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the 
published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the 
interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.
Cover photos: Mr Masanori Matsuoka
Guidelines for the diagnosis, treatment and prevention of leprosy iii
Contents
Abbreviations and acronyms ........................................................................................... v
Acknowledgements ....................................................................................................... vii
Contributors .................................................................................................................viii
Executive summary ........................................................................................................ xi
Part I: Guideline development process ............................................................................1
1. Introduction ..................................................................................................1
2. Rationale ......................................................................................................3
3. Target audience ............................................................................................4
4. Goals and objectives .....................................................................................4
5. Methods .......................................................................................................4
6. Key questions ................................................................................................7
7. Systematic review methods .........................................................................10
8. Assessment of the quality of the evidence ...................................................10
9. Values, preferences and ethical considerations ............................................11
10. Formulation of recommendations ...............................................................12
Part II: Recommendations .............................................................................................15
1. Diagnosis ....................................................................................................15
2. Treatment for leprosy ..................................................................................16
3.  Prophylaxis .................................................................................................21
4. Implementation and evaluation ...................................................................24
5. Updating ....................................................................................................25
Part III: Research priorities ............................................................................................27
1. Leprosy diagnosis ........................................................................................27
2. Leprosy treatment .......................................................................................27
3. Prevention of leprosy ..................................................................................28
References ....................................................................................................................29
Annexes
1. Summary on review of conflicts of interest ...........................................................36
2. Evidence-to-recommendation tables ....................................................................39
3. Guide for the focus group discussions to identify values and preferences 
of persons affected by leprosy ..............................................................................84
4. GRADE tables and literature review report ...........................................................87

Guidelines for the diagnosis, treatment and prevention of leprosy v
Abbreviations and acronyms
BCG bacille Calmette-Guérin
CI confidence interval
COLEP prospective sero-epidemiological study on contact transmission and 
chemoprophylaxis in leprosy
CRE Office of Compliance, Risk Management and Ethics
DNA deoxyribonucleic acid
DOI Declaration of Interest
ELISA enzyme-linked immunosorbent assay
EPI Expanded Programme on Immunization
ERG External Review Group
GDG Guidelines Development Group
GLP Global Leprosy Programme
GRADE Grading of Recommendations, Assessment, Development and Evaluation 
GRC Guidelines Review Committee
HIV human immunodeficiency virus
IDRI Infectious Disease Research Institute 
ILEP International Federation of Anti-Leprosy Associations
LPEP Leprosy Post-Exposure Prophylaxis
LRI Leprosy Research Initiative
MB multibacillary
MDA mass drug administration
MDT multidrug therapy
NDO-LID  natural disaccharide octyl-leprosy IDRI diagnostic 
NGO nongovernmental organization
NTD neglected tropical disease
PB paucibacillary
Guidelines for the diagnosis, treatment and prevention of leprosyvi
PCR  polymerase chain reaction
PICO   population, intervention, comparator, outcome
PPV  positive predictive value
QUADAS  Quality Assessment of Diagnostic Accuracy Studies
RCT  randomized controlled trial
RR  relative risk
RRR  relative risk reduction
SAGE  Strategic Advisory Group of Experts on Immunization
SDR  single-dose rifampicin
SOE  sum of errors
TB  tuberculosis
UMDT  uniform MDT
UN  United Nations
US$  United States dollar
WHO  World Health Organization
Guidelines for the diagnosis, treatment and prevention of leprosy vii
Acknowledgements
The development of these guidelines was coordinated by Laura Gillini, Medical Oﬃ  cer, Global 
Leprosy Programme (GLP) and supervised by Erwin Cooreman, GLP Team Leader.
The GLP would like to thank members of the Guidelines Development Group (GDG), 
members of the External Review Group (ERG), and World Health Organizati on (WHO) staﬀ  who 
contributed to the development of these guidelines as part of the Steering Group or as peer 
reviewers. The GLP appreciates the input provided by the nati onal leprosy programmes of the 
following countries: Colombia, the Democrati c Republic of the Congo, India, Morocco and the 
Philippines. The GLP is parti cularly grateful to the persons aﬀ ected by leprosy who parti cipated 
in focus group discussions in Colombia, Ghana, India and Nepal on diagnosis, treatment and 
contact screening.
The guidelines for the diagnosis, treatment and preventi on of leprosy were developed 
with full funding support from The Nippon Foundati on.
Guidelines for the diagnosis, treatment and prevention of leprosyviii
Contributors
These guidelines were a collaborative effort between the GDG, a methodologist, a systematic 
reviewer, ERG and the WHO Steering Group. The GDG and ERG included persons affected 
by leprosy. All contributors completed a WHO Declaration of Interest (DOI) form (summarized 
in Annex 1).
Guidelines Development Group
The GDG consisted of the following persons: Professor Jacques Grosset (Chair), Emeritus 
Professor of Medicine, Johns Hopkins University, he lives in France; Professor Marcos Boulos, 
University of Sao Paulo, Brazil; Professor Emmanuelle Cambau, University Paris Diderot, 
France; Professor Sang Nae Cho, Yonsei University College of Medicine, Republic of Korea; 
Professor Nilanthi R. da Silva, University of Kelaniya, Sri Lanka; Dr Sara Irène Eyangoh, 
Centre Pasteur du Cameroun, Cameroon; Dr Deanna Hagge, Anandabad Hospital, Nepal; 
Dr Marie Jocelyn Te, Regional Leprosy Control and Prevention Program, Ministry of Health, 
the Philippines; Dr Willem (Pim) Kuipers, International Federation of Anti-Leprosy Associations 
(ILEP), he lives in Australia; Dr Anil Kumar, National Leprosy Eradication Programme, Ministry 
of Health and Family Welfare, India; Professor Bhushan Kumar, Shalby Multispecialty Hospital, 
India; Professor Mourad Mokni, University of Tunis, Tunisia; Dr Indranil Mukhopadhyay, 
Public Health Foundation of India, India; Mr Vagavathali Narsappa, Association of People 
Affected by Leprosy, India; Professor Travis Porco, The Francis I. Proctor Foundation, 
Department of Epidemiology and Biostatistics and Department of Ophthalmology, University 
of California, United States of America; Dr Paul Saunderson, American Leprosy Missions, 
Chair ILEP Technical Commission, he lives in Norway; Dr Vineeta Shanker, Sasakawa-India 
Leprosy Foundation, India; Dr Cita Rosita Sigit Prakoeswa, Faculty of Medicine, Universitas 
Airlangga-Dr Soetomo Teaching Hospital, Indonesia; Professor W. Cairns Smith, Emeritus 
Professor of Epidemiology, School of Medicine and Dentistry, Aberdeen University, United 
Kingdom; Professor Marcos Virmond, Instituto Lauro de Souza Lima, Brazil; Dr Rie Yotsu, 
National Suruga Sanatorium, Japan.
Methodologist
The methodologist was Professor Roger Chou, Department of Medical Informatics and 
Clinical Epidemiology and Department of Medicine, Oregon Health and Science University, 
United States of America.
Guidelines for the diagnosis, treatment and prevention of leprosy ix
Systematic reviewer
The systematic reviews of evidence for these guidelines were conducted by Dr Amudha 
Poobalan, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and 
Nutrition, University of Aberdeen, United Kingdom.
External Review Group
The ERG consisted of the following persons:
Dr Shengelia Bakhuti, Novartis Foundation, Switzerland; Dr Marivic F. Balagon, Leonard 
Wood Memorial Center for Tuberculosis and Leprosy Research, the Philippines; Dr Wim 
H. van Brakel, Netherlands Leprosy Relief, the Netherlands; Mrs Paula Soares Brandao, 
Panel of Women and Men Affected by Leprosy (ILEP), she lives in Brazil; Dr Hughes Davis, 
Novartis Global Drug Development, Switzerland; Mr Mathias Duck, Panel of Women and 
Men Affected by Leprosy (ILEP), he lives in Paraguay; Professor N.K. Ganguly, National 
Institute of Immunology, India; Professor Mohan D. Gupte, Chair Technical Advisory Group 
on Leprosy, India; Professor Eliane Ignotti, Mato Grosso State University, Brazil; Dr Herman-
Joseph Kawuma, German Tuberculosis and Leprosy Relief Association, Uganda; Dr Ibtissam 
Khoudri, National Leprosy Programme, Ministry of Health, Morocco; Mrs Rachna Kumari, 
Panel of Women and Men Affected by Leprosy (ILEP), she lives in India; Dr Jean Norbert 
Mputu Luengu, National Leprosy Programme, Ministry of Health, Democratic Republic of 
the Congo; Professor Takahiro Nanri, Sasakawa Memorial Health Foundation, Japan; Mr Kofi 
Nyarko, Panel of Women and Men Affected by Leprosy (ILEP), he lives in Ghana; Professor 
Jan Hendrik Richardus, Erasmus Medical Center, Rotterdam University, the Netherlands; 
Mr Amar Bahadur Timalsina, Panel of Women and Men Affected by Leprosy (ILEP), he 
lives in Nepal; Dr Nestor Vera, National Leprosy Programme, Ministry of Health and Social 
Protection, Colombia; Professor Mitchell G. Weiss, Swiss Tropical and Public Health Institute 
and University of Basel, Switzerland.
WHO Steering Group
The WHO Steering Group included members with expertise in the areas of intellectual 
property, evaluation of essential medicines, management of neglected tropical diseases 
(NTDs), and gender, equity, and human rights. The members were:
Dr Erwin Cooreman, Chair, GLP, WHO Regional Office for South-East Asia
Dr Laura Gillini, GLP, WHO Regional Office for South-East Asia
Dr VRR Pemmaraju, GLP, WHO Regional Office for South-East Asia
Guidelines for the diagnosis, treatment and prevention of leprosyx
Dr Manisha Shridar, Public Health, Innovation and Intellectual Property, WHO Regional 
Office for South-East Asia
Dr Klara Tisocki, Policy, Access and Use, WHO Regional Office for South-East Asia
Dr Md. Jamsheed Ahmed, Neglected Tropical Diseases, WHO Regional Office for South-
East Asia
Dr Davison Munodawafa, Human Rights and Gender, WHO Regional Office for Africa
Dr Eduardo Calderon Pontaza, Human Rights, Office of Legal Counsel, Pan-American Health 
Organization/WHO Regional Office for the Americas
Mr Dimitry Esin, Neglected Tropical Diseases, WHO headquarters
Dr Linh Nguyen-Nhat, Global Tuberculosis Programme, WHO headquarters
Guidelines for the diagnosis, treatment and prevention of leprosy xi
Executive summary
Background
Leprosy is a disease that predominantly affects the skin and peripheral nerves, resulting in 
neuropathy and associated long-term consequences, including deformities and disabilities. 
The disease is associated with stigma, especially when deformities are present. Despite the 
elimination of leprosy as a public health problem (defined as achieving a point prevalence 
of below 1 per 10 000 population) globally in 2000 and at a national level in most countries 
by 2005, leprosy cases continue to occur. Over 200 000 new leprosy cases were reported 
in 2016. Therefore, guidance on early diagnosis and treatment of leprosy is essential for 
reducing the burden of this disease.
Leprosy is classified as paucibacillary (PB) or multibacillary (MB), based on the number 
of skin lesions, presence of nerve involvement and identification of bacilli on slit-skin smear. 
The standard treatment for leprosy involves the use of multiple (two or three) drugs; the 
duration of treatment, dose and number of antibiotics depend on the type of leprosy (PB or 
MB) and age of the patient (adult or child). Strategies to prevent leprosy include vaccination 
or use of prophylactic antibiotics among persons with exposure.
Rationale and methods
The purpose of these WHO guidelines is to provide evidence-based recommendations on 
the diagnosis, treatment and prevention of leprosy, utilizing WHO guideline development 
methods based on the GRADE1 process. Previous leprosy guidance documents were 
developed through Expert Committee meeting reports and/or through other technical 
documents, without a formal guideline development process. For prevention of leprosy, 
these guidelines focus on the use of antibiotics (chemoprophylaxis). Although vaccinations 
could prevent leprosy, WHO regulations require that the Strategic Advisory Group of Experts 
on Immunization (SAGE) formulate all vaccination (immunoprophylaxis) recommendations. 
Therefore, the Guidelines Development Group (GDG) reviewed evidence on vaccinations 
but did not formulate recommendations; rather, findings on vaccinations were shared with 
the SAGE bacille Calmette-Guérin (BCG) working group to help inform its recommendations.
The primary audience for these WHO guidelines includes persons involved in leprosy 
policy formulation and clinicians who manage leprosy, particularly in low- and middle-
income countries.
1 GRADE: Grading of Recommendations Assessment, Development and Evaluation
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These guidelines were developed in accordance with procedures established by the 
WHO Guidelines Review Committee (GRC). The scope of the guidelines and associated 
systematic reviews was determined in October 2016. Systematic reviews were commissioned 
to address the key questions developed in the scoping process on diagnosis, treatment and 
prevention of leprosy. Recommendations were formulated by a regionally representative 
and multidisciplinary GDG at a meeting held in May 2017 and in a subsequent meeting 
in October 2017 held upon availability of additional evidence. The GRADE approach was 
used to formulate and categorize the strength of recommendations (strong or conditional), 
and was adapted for questions related to diagnostic tests. GRADE includes an assessment 
of the quality of evidence (high, moderate, low or very low), consideration of the overall 
balance of benefits to harms (at individual and population levels), patient/health worker 
values and preferences, resource use, effects on equity, cost–effectiveness and consideration 
of feasibility and effectiveness across a variety of settings, including resource-limited settings 
and those in which access to laboratory infrastructure and specialized tests is limited. There 
was no evidence on benefits and harms of treatment for drug-resistant leprosy; therefore, 
recommendations for this topic were based on expert opinion. The process also identified 
other key research gaps to help inform the future research agenda for leprosy. These guidelines 
do not address the programmatic aspects of leprosy management, which is covered by the 
WHO Global Leprosy Strategy 2016–2020 “Accelerating towards a leprosy-free world” and 
its accompanying Operational Manual and Monitoring and Evaluation Guide.
Summary of recommendations
Table 1 summarizes the recommendations on diagnosis, treatment and prevention of leprosy 
with antibiotics (chemoprophylaxis).
Diagnosis of leprosy
The guidelines recommend no additional tests in addition to standard methods for diagnosis 
of leprosy: the diagnosis of leprosy remains based on the presence of at least one of three 
cardinal signs: (i) definite loss of sensation in a pale (hypopigmented) or reddish skin patch; 
(ii) thickened or enlarged peripheral nerve with loss of sensation and/or weakness of the 
muscles supplied by that nerve; or (iii) presence of acid-fast bacilli in a slit-skin smear. The 
clinical diagnosis of early leprosy and PB leprosy can be a challenge. Therefore, a number 
of serological and other laboratory assays have been developed to supplement clinical 
diagnostic methods. However, enzyme-linked immunosorbent assays (ELISA) and lateral flow 
assays are associated with low diagnostic accuracy for PB leprosy. Although some polymerase 
chain reaction (PCR)-based assays are associated with higher diagnostic accuracy, they lack 
standardization, are not commercially available, and would be difficult to perform in most 
primary health-care settings.
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The guidelines also do not recommend any test for the diagnosis of leprosy in 
asymptomatic contacts. The predictive accuracy of diagnostic tests for identifying persons 
who will develop leprosy is low, with poor positive predictive values.
Treatment of leprosy
The guidelines recommend a 3-drug regimen of rifampicin, dapsone and clofazimine for all 
leprosy patients, with a duration of treatment of 6 months for PB leprosy and 12 months for 
MB leprosy. This represents a change from the current standard treatment for PB leprosy, 
which is rifampicin and dapsone for 6 months, due to some evidence indicating better 
clinical outcomes with a 3-drug, 6-month regimen over a 2-drug, 6-month regimen. A 
potential advantage of using the same three drugs for PB and MB leprosy is simplification 
of treatment (i.e. the same blister pack could be used for treating both types of leprosy) and 
reduced impact of misclassification of MB leprosy as PB leprosy, since all patients will receive 
a 3-drug regimen. For MB leprosy, the current standard treatment is a 3-drug regimen for 12 
months. Evidence on the potential benefits and harms of a shorter (6-month) 3-drug regimen 
was limited and inconclusive, with a potential increase in the risk of relapse. Therefore, the 
GDG determined that there was not enough evidence of equivalent outcomes to support a 
recommendation to shorten the treatment duration for MB leprosy.
For rifampicin-resistant leprosy, the guidelines recommend treatment with at least two 
second-line drugs (clarithromycin, minocycline or a quinolone) plus clofazimine daily for 
6 months, followed by clofazimine plus one of these drugs for an additional 18 months. 
When ofloxacin resistance is also present, a fluoroquinolone should not be used as part 
of second-line treatment. The regimen of choice in such cases shall consist of 6 months of 
clarithromycin, minocycline and clofazimine followed by clarithromycin or minocycline plus 
clofazimine for an additional 18 months.
Resistance has been reported from several countries, although the number of patients is 
small. Evidence on the potential benefits and harms of alternative regimens for drug-resistant 
leprosy was not available. Therefore, recommendations for second-line regimens are based 
on expert opinion and the known activity of alternative drugs, including the likelihood of 
cross-resistance.
Prevention of leprosy through chemoprophylaxis
The guidelines recommend the use of single-dose rifampicin (SDR) as preventive treatment for 
adult and child (2 years of age and above) contacts of leprosy patients, after excluding leprosy and 
tuberculosis (TB) disease and in the absence of other contraindications. The COLEP2 randomized 
controlled trial (RCT) found SDR in leprosy contacts associated with a 57% reduction in the 
risk of leprosy after 2 years and 30% after 5–6 years; SDR also appears highly cost–effective, 
with an incremental cost–effectiveness ratio of US$ 158 per additional prevented leprosy case.
2 COLEP: prospective sero-epidemiological study on contact transmission and chemoprophylaxis in leprosy
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The ability of programmes to adequately identify and manage contacts of persons with 
leprosy is a prerequisite for successful implementation of the recommendation. Because 
leprosy is highly stigmatized, caution must be exercised when implementing SDR, particularly 
for contacts outside the patient’s family. Programmes must respect the wish of patients to 
disclose or not disclose their diagnosis. When patients do not authorize disclosure, the 
GDG does not recommend identification or screening of contacts, which is a prerequisite 
for prescribing preventive treatment. In hyperendemic settings, a blanket approach (i.e. 
treatment of all community members without identifying contacts) might be more feasible 
and reduce potential harms related to disclosure of a leprosy diagnosis.
Table 1. Recommendations on diagnosis, treatment and chemoprophylaxis 
of leprosy (summary)
Area of the 
recommendation Recommendation Strength
Quality of 
evidence
Diagnosis
Diagnosis of leprosy The diagnosis of leprosy may be 
based on clinical examination, 
with or without slit-skin smears 
or pathological examination of 
biopsies.
Conditional Low
Diagnosis of leprosy 
infection
There is currently no test 
recommended to diagnose leprosy 
infection (latent leprosy) among 
asymptomatic contacts.
Conditional Low
Treatment
Treatment of leprosy The same 3-drug regimen 
of rifampicin, dapsone and 
clofazimine may be used for all 
leprosy patients, with a duration 
of treatment of 6 months for PB 
leprosy and of 12 months for MB 
leprosy.
Conditional Low
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Area of the 
recommendation Recommendation Strength
Quality of 
evidence
Treatment of drug-
resistant leprosy
Leprosy patients with rifampicin 
resistance may be treated using at 
least two of the following second-line 
drugs: clarithromycin, minocycline or 
a quinolone (ofloxacin, levofloxacin or 
moxifloxacin), plus clofazimine daily 
for 6 months, followed by clofazimine 
plus one of the second-line drugs daily 
for an additional 18 months.
Leprosy patients with resistance to 
both rifampicin and ofloxacin may 
be treated with the following drugs: 
clarithromycin, minocycline and 
clofazimine for 6 months followed 
by clarithromycin or minocycline 
plus clofazimine for an additional 
18 months.
Conditional No evidence 
retrieved (based 
on expert 
opinion)
Prevent ion
Chemoprophylaxis 
for contacts of 
patients with leprosy
Single-dose rifampicin (SDR) may 
be used as leprosy preventive 
treatment for contacts of leprosy 
patients (adults and children aged 
2 years and above), after excluding 
leprosy and tuberculosis (TB) 
disease, and in the absence of 
other contraindications.
This intervention shall be 
implemented only by programmes 
that can ensure: (i) adequate 
management of contacts, and 
(ii) consent of the index case to 
disclose his/her disease.
Conditional Moderate
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Part I: Guideline development process
1. Introduction
Leprosy is a disease that predominantly affects the skin and peripheral nerves, resulting in 
neuropathy and associated long-term consequences, including deformities and disability. 
While in previous times it was common in temperate climates (e.g. Europe), today leprosy 
is mainly confined to tropical and subtropical regions. The disease is associated with stigma, 
especially when deformities are present. Transmission of leprosy is poorly understood, 
although it is thought to be through inhalation of droplets containing the causative agent, 
Mycobacterium leprae (M. leprae). However, transmission via skin contact or other means 
cannot be entirely excluded. Leprosy has a reservoir in armadillos and a few other animals.
Up to 95% of patients exposed to M. leprae will not develop the disease, suggesting that 
host immunity plays an important role in disease progression and control. The incubation 
time is variable, ranging from 2 to 20 years, or longer.
The fight against leprosy has achieved considerable success, as evidenced by the 
elimination of leprosy as a public health problem (defined as a point prevalence below 1 
per 10 000 population) in 2000 globally and at the national level in most countries by 2005. 
However, the number of new patients diagnosed with leprosy is still significant, at more than 
200 000 in 2016 (1). The new case detection rate of the disease (a proxy for incidence rate) 
is only slowly declining (Fig. 1).
Fig. 1 . Trend in case detection and case detection rate, by WHO Region, 2006–2016
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Leprosy is diagnosed by finding at least one of the following cardinal signs:
(1) definite loss of sensation in a pale (hypopigmented) or reddish skin patch;
(2) thickened or enlarged peripheral nerve, with loss of sensation and/or weakness 
of the muscles supplied by that nerve;
(3) presence of acid-fast bacilli in a slit-skin smear.
Leprosy is a highly variable disease, affecting different people in different ways, 
according to their immune response. Those at one end of the spectrum, with a high level of 
immunity, harbour a low number of bacilli and are referred to as patients with PB leprosy. 
Those with many bacilli in the body are referred to as patients with MB leprosy. In 2016, 
WHO launched the Global Leprosy Strategy 2016–2020 “Accelerating towards a leprosy-free 
world” (2) and in 2017, WHO revised the case definitions of PB and MB leprosy, through 
the release of a Monitoring and Evaluation Guide to the Global Strategy (3), as follows:
Paucibacillary (PB) case: a case of leprosy with 1 to 5 skin lesions, without demonstrated 
presence of bacilli in a skin smear;
Multibacillary (MB) case: a case of leprosy with more than five skin lesions; or with 
nerve involvement (pure neuritis, or any number of skin lesions and neuritis); or with the 
demonstrated presence of bacilli in a slit-skin smear, irrespective of the number of skin lesions.
Early diagnosis and complete treatment with multidrug therapy (MDT) remain the key 
strategies for reducing the disease burden of leprosy. In addition, BCG vaccine is an effective 
tool for prevention of leprosy. Standard MDT regimens for PB (two drugs) and MB (three 
drugs) leprosy were introduced in 1982, with a duration of treatment of 6 months for PB 
leprosy and from initially minimum 24 months and in 1998 reduced to 12 months for MB 
leprosy upon a recommendation by the WHO Expert Committee (4). MDT is provided in 
blister packs, each containing 4 weeks’ treatment. Specific blister packs are available for MB 
and PB leprosy, with different doses for adults and children, as shown below:
The standard adult treatment regimen for MB leprosy is:
Rifampicin:  600 mg once a month
Clofazimine: 300 mg once a month, and 50 mg daily
Dapsone:  100 mg daily
Duration:  12 months (12 blister packs of 28 days each)
The standard adult treatment regimen for PB leprosy is:
Rifampicin:  600 mg once a month
Dapsone:  100 mg daily
Duration:  6 months (6 blister packs of 28 days each)
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Standard child (ages 10–14 years) treatment regimen for MB leprosy is:
Rifampicin:  450 mg once a month
Clofazimine: 150 mg once a month, and 50 mg every other day
Dapsone:  50 mg daily
Duration:  12 months (12 blister packs of 28 days each)
The standard child (ages 10–14 years) treatment regimen for PB leprosy is:
Rifampicin:  450 mg once a month
Dapsone:  50 mg daily
Duration:  6 months (6 blister packs of 28 days each)
MDT is provided free-of-charge globally through an agreement between a 
pharmaceutical company and WHO. WHO manages distribution of MDT to countries in 
coordination with national leprosy programmes.
To date, no WHO recommendations on preventive strategies have been issued, though 
research on different antibiotics and combinations of antibiotics have been carried out since 
the 1990s.
2. Rationale
A WHO leprosy guideline using current WHO methods for guideline development is needed 
following demands from Member States for proper guidance in specific programme areas. 
Previous leprosy WHO guidance documents on clinical and public health aspects of leprosy 
were developed through expert committees and disseminated as committee meeting reports 
and/or other technical documents, without using a formal guideline development process 
(i.e. systematic evidence review or application of GRADE methods). The last WHO guidance 
on leprosy was issued in 2010 (5) and the one previous to that was issued in 1998 (4).
A leprosy guideline is also needed to incorporate new evidence and address areas 
of clinical uncertainty in the diagnosis, treatment and prevention of leprosy. Diagnosis of 
early leprosy, particularly PB leprosy, remains a challenge, and a diagnostic test to detect 
early leprosy could be a key tool for preventing transmission, initiating early treatment, and 
preventing disabilities due to leprosy (6). Furthermore, although prevention of leprosy is 
preferable to treating clinical disease, prior WHO guidance does not address prevention. 
In the absence of WHO evidence-based guidelines, some countries have issued their own 
policies on prevention (7). Drug-resistant leprosy has been identified in several countries 
(10,11), but there is no recent WHO guidance on treatment of drug-resistant leprosy. 
Surveillance guidelines for monitoring drug resistance in leprosy were issued by WHO in 
2009 (8) with an updated guide published in October 2017 (9). Therefore, the guidelines 
need to address treatment for leprosy, including use of standard MDT, with different regimens 
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for PB and MB leprosy, versus alternatives such as uniform MDT (UMDT), in which the same 
3-drug 6-month regimen is used for both PB and MB leprosy.
3. Target audience
The objective of these guidelines is to provide policy-makers in ministries of health and 
medical staff working in low- and middle-income countries with recommendations on 
current tools to diagnose leprosy, on drug combinations for leprosy treatment and on 
preventive chemotherapy. These guidelines are also intended to assist officials as they develop 
national leprosy plans and guidelines. In addition, the guidelines will assist persons working 
in nongovernmental organizations (NGOs) that provide leprosy services to define relevant 
elements of the services they offer. The guidelines are intended to be helpful to clinicians 
who treat leprosy patients, and to researchers by highlighting gaps in research. The guidelines 
may be useful for donors to identify priorities for future funding.
4. Goals and objectives
The overall goal of these guidelines is to provide guidance and evidence-based 
recommendations for the diagnosis, treatment and prevention of leprosy. For prevention of 
leprosy, these guidelines focus on use of antibiotics (chemoprophylaxis). The primary audience 
for these WHO guidelines consists of persons involved in the formulation of policy for leprosy 
and clinicians who manage leprosy, particularly in low- and middle-income countries.
5. Methods
5.1 Contributors to guideline development
A number of groups contributed to the development of these guidelines. The roles and 
responsibilities of each of these groups are described below:
WHO Steering Group
The WHO Steering Group included staff members with expertise in the areas of leprosy, 
disease control, intellectual property, evaluation of essential medicines, management of NTD, 
and gender, equity, and human rights. The Steering Group contributed to the key questions, 
provided input to the planning process of the guidelines, and reviewed draft documents 
including the planning proposal, the literature reviews, and the draft guidelines.
Guidelines Development Group
The task of the GDG was to review the evidence as summarized in the systematic reviews 
and to develop recommendations. The GDG members consisted of persons with expertise 
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in diagnosis and management of leprosy (clinicians), persons affected by leprosy, civil society 
and non-state implementers (NGOs), and experts in the programmatic management of 
leprosy and in implementation. Diversity was sought with regard to gender, geographical 
representation, and intellectual perspectives. Given the disproportionate burden of the 
disease in the WHO South-East Asia Region, the Secretariat ensured representation from 
this Region in the GDG and ERG. The GDG met twice to develop these guidelines, once in 
New Delhi, India on 30–31 May 2017 and once via teleconference on 27 October 2017. 
The purpose of the second meeting was to review additional evidence published in August 
2017 on treatment of leprosy. Recommendations were developed following discussion and 
consensus was sought on all recommendations. All recommendations were unanimous.
Other external contributors
Systematic review team
The WHO Secretariat commissioned systematic reviews on the diagnosis, treatment and 
prevention of leprosy. The reviews team was led by Dr Amudha Poobalan from the Institute 
of Applied Health Sciences, Aberdeen University, United Kingdom.
External Review Group
The ERG was composed of individuals with relevant expertise in leprosy, including disease/
health programme implementation. The role of ERG was to identify any errors or missing 
data, to comment on clarity, to highlight specific issues and implications for implementation 
but not to modify the recommendations agreed by the GDG. Members of the ERG were 
identified after the GDG meeting in May 2017. The Secretariat ensured regional and gender 
balance and representation of different areas of expertise (clinical, public health, social 
sciences). A Declaration of Interest form was collected from all ERG members. The ERG 
included persons from the ILEP Panel of Women and Men Affected by Leprosy. This panel 
is composed of five affected persons from different countries (Brazil, Ghana, India, Nepal 
and Paraguay). Reviewers were required to disclose conflicts of interest. Because reviewers 
were not involved in the formulation of recommendations, presence of conflicts did not 
disqualify them.
Guidelines methodologist
The methodologist oversaw the entire process of collection and grading of evidence and 
facilitated the discussions during the GDG meetings, acting as vice-chair. The methodologist 
for these guidelines was Professor Roger Chou, Department of Medical Informatics and 
Clinical Epidemiology and Department of Medicine, Oregon Health and Science University, 
United States of America.
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External partners
The key partner organizations involved in the review and dissemination of the guidelines 
document were:
 • ILEP and its members (14 international NGOs working in the field of leprosy);
 • The Nippon Foundation;
 • Sasakawa Memorial Health Foundation (also an ILEP member).
The Nippon Foundation and the Sasakawa Memorial Health Foundation have been 
major donors to GLP for many years. Three of their staff attended the GDG meetings as 
observers. As observers they were not involved in the formulation of the recommendations.
5.2 Management of conflicts of interest
Management of conflicts of interest was a key task throughout the guideline development 
process. Before their appointment to the GDG or ERG, all potential members submitted a 
Declaration of Interest form. The GLP Team Leader, along with the Office of Compliance, Risk 
Management and Ethics (CRE) in WHO headquarters, reviewed the declarations and sought 
clarifications when necessary. The declarations were also submitted by the contractor for the 
literature review and the methodologist. All potential conflicts were assessed to determine 
whether any of several conflicts were warranted: exclusion from the panel; exclusion from 
one or more topic areas; inclusion in all of the evidence review sessions, but exclusion from 
final voting on recommendations; or no action required. Conflicts of interest were also 
reviewed at the beginning of the two GDG meetings and new disclosures assessed using 
the same process. In accordance with WHO policies, the Secretariat posted the names and 
biographies of all GDG members one month before the GDG meeting on WHO websites. 
No individual was determined to have a financial or non-financial conflict of interest that 
required exclusion from participation in any of the topics discussed. To ensure transparency, 
the details of each member’s association with commercial organizations (with or without 
financial interests) within the last year, as well as potential intellectual conflicts, were shared 
with other members of the group, and the GDG members confirmed their disclosures. A 
summary of conflicts of interests declared by the ERG and GDG members and how conflicts 
were addressed is given in Annex 1.
In accordance with the WHO policies, the Secretariat posted on WHO websites the 
names and biographies of all GDG members 1 month before the first GDG meeting. Neither 
comments nor observations were received.
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6. Key questions
The Steering Group developed the key questions used to guide the systematic review. The 
key questions were formulated using the PICO (Population, Intervention, Comparator and 
Outcomes) format. The questions addressed by the systematic review were as follows:
6.1. Questions on leprosy diagnosis
Question 1a: Is there a diagnostic test for leprosy disease (PB and/or MB) that has 
sufficient sensitivity and specificity and whose use is feasible under programmatic 
conditions?
Population Intervention Comparator Outcomes
Adults and 
children 
with 
suspected 
leprosy and 
leprosy 
patients (PB 
and MB) 
diagnosed 
clinically
• Tests that detect 
M. leprae nucleic acids 
(PCR), antigens or other 
components
• Tests that detect host 
biomarkers such as 
antibodies (i.e. PGL-1 or 
NDO-LID) or chemokines 
and cytokines (i.e. IP-10, 
IL-10) or that detect 
antibodies together with 
chemokines and cytokines
• Tests that detect “effects of 
the disease” such as nerve 
enlargement by ultrasound
Diagnosis of leprosy on the 
basis of having one or more 
of the following:
• definite loss of sensation 
in a hypopigmented or 
reddish skin patch;
• thickened or enlarged 
peripheral nerve, with 
loss of sensation and/or 
weakness of the muscles 
supplied by that nerve;
• presence of acid-fast bacilli 
in a slit-skin smear or in a 
skin biopsy
• histopathological diagnosis 
(skin/nerve-biopsy)
• sensitivity
• specificity
• predictive 
values
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Question 1b: Is there a diagnostic test that has sufficient sensitivity and specificity 
to diagnose M. leprae infection (latent leprosy) among contacts and whose use is 
feasible under programmatic conditions?
Population Intervention Comparator Outcomes
Contacts of patients 
with leprosy:
• contacts of patients 
with PB leprosy
• contacts of patients 
with MB leprosy
• household contacts 
(of PB and MB)
• social contacts (of 
PB and MB)
• neighbours of 
patients with leprosy 
(PB and MB)
• Tests that 
detect host 
biomarkers 
such as 
antibodies 
(i.e. PGL-1 or 
NDO-LID) or 
chemokines 
and cytokines 
(i.e. IP-10, 
IL-10) or 
that detect 
antibodies 
together with 
chemokines 
and cytokines
Diagnosis of leprosy based 
on the basis of having one or 
more of the following:
• definite loss of sensation 
in a hypopigmented or 
reddish skin patch;
• thickened or enlarged 
peripheral nerve, with 
loss of sensation and/or 
weakness of the muscles 
supplied by that nerve;
• presence of acid-fast 
bacilli in a slit-skin smear 
or in tissue/biopsy
• histopathological diagnosis 
over a biopsy
• sensitivity
• specificity
• predictive values
• adverse effects
6.2. Questions on leprosy treatment
Question 2a: Is a single (uniform) treatment regimen for all patients with leprosy as 
effective and safe as the two currently recommended treatment regimens: the one 
for MB leprosy with a combination of three drugs for 12 months and the one for PB 
leprosy with a combination of two drugs for 6 months?
Population Intervention Comparator Outcomes
Leprosy patients:
• PB
• MB
Single regimen for 
both PB and MB 
(MDT with three 
drugs: rifampicin, 
dapsone and 
clofazimine) for 6 
months
• 6 months MDT 
regimen with 
rifampicin + 
dapsone for 
PB leprosy
• 12 months 
MDT regimen 
with rifampicin 
+ dapsone + 
clofazimine for 
MB leprosy
• Cure (treatment completion, 
clinical improvement)
• Disease relapse
• Drug adverse events
• Cost–effectiveness
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Question 2b: Which treatment regimen has better effectiveness and safety for leprosy 
patients detected with resistance to rifampicin, with or without associated resistance 
to dapsone or ofloxacin?
Population Intervention Comparator Outcomes
Leprosy patients 
infected with strains 
showing DNA 
mutations associated 
with drug resistance 
to rifampicin alone or 
in combination with 
resistance to dapsone 
and/or fluoro-
quinolones
• 400 mg ofloxacin + 
100 mg minocycline 
+ 50 mg clofazimine, 
daily for 6 months; 
followed by 400 mg 
ofloxacin daily
• 100 mg minocycline 
+ 50 mg clofazimine 
for at least 18 months
12 months 
MDT regimen 
(rifampicin+ 
dapsone + 
clofazimine)
• Cure (treatment 
completion), clinical 
improvement
• Disease relapse
• Drug adverse events
• Cost–effectiveness
6.3. Questions on leprosy prevention
Question 3a: Is there an effective and safe chemoprophylaxis regimen for the 
prevention of leprosy among contacts of leprosy patients and for other high-risk 
populations that could be used under programmatic conditions?
Population Intervention Comparator Outcomes
• Contacts of leprosy patients
• High-risk populations (living in 
highly endemic areas where a 
case has been detected)
SDR 600 mg No preventive 
treatment
• Leprosy disease
• Cost–effectiveness
• Drug adverse events
Question 3b: Is there an effective vaccine for the prevention of leprosy that could be 
used under programmatic conditions, with or without chemoprophylaxis, for contacts 
of leprosy patients and also among the general population?
Population Intervention Comparator Outcomes
• General 
population
• Contacts 
of leprosy 
patients
• BCG at birth ± SDR 600 mg for 
adults (10/15 mg kg for children)
• BCG revaccination ± SDR 600 mg 
for adults (10/15 mg kg for children)
• BCG + M. leprae vaccine
• ICRC vaccine
• M. indicum pranii vaccine
• LepVax (IDRI)
• No 
vaccination
• BCG at 
birth only
• Leprosy disease
• Vaccine adverse 
events:
 – Serious adverse 
events
 – Mild adverse events
Guidelines for the diagnosis, treatment and prevention of leprosy10
7. Systematic review methods
The systematic reviews were conducted by an independent reviewer commissioned by WHO. 
The WHO Steering Group and the methodologist provided oversight, including assessing and 
providing feedback on the protocol for each systematic review against the corresponding 
PICO question and the accompanying evidence tables, and checking data extraction.
Literature search strategy
Literature searches were conducted using terms for leprosy, diagnostic tests, antibiotic 
treatment and vaccinations, on the following databases: Embase, MEDLINE, and the Cochrane 
Central Register of Controlled Trials. For laboratory tests inclusion was limited to studies 
published after 1996, as laboratory techniques and processes have changed over the past 
20 years and older studies were considered less relevant to current practice.
Data extraction methods
After relevant studies were identified, eligibility was confirmed by the reviewer and the GLP 
team. Data extraction was conducted by the reviewer and members of the Steering Group; 
the methodologist also checked a random sample of extracted studies. Risk of bias for each 
study was assessed using the Cochrane Risk of Bias tool for intervention studies or a tool 
designed for assessment of diagnostic accuracy studies, the QUADAS-2 tool (16).
Meta-analysis
Meta-analysis was not conducted due to the small number of studies, methodological 
limitations in the studies, and heterogeneity across studies in populations, interventions and 
outcomes addressed.
Cost–effectiveness analysis
Cost–effectiveness is an important consideration for the development of leprosy guidelines. 
However, for most PICO questions no studies on cost–effectiveness were identified. The 
exception was preventive treatment, for which one published cost–effectiveness study was 
found and reviewed (13). Its results were taken into consideration when formulating the 
recommendation.
8. Assessment of the quality of the evidence
The quality/certainty of the body of evidence for each question was assessed using the 
GRADE method, modified for evaluation of diagnostic tests as appropriate (14,15). The 
quality of evidence was categorized as high, moderate, low or very low (Table 2). In GRADE, 
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RCTs start as high quality. Although observational studies of interventions start as low quality 
in GRADE, for diagnostic accuracy, cross-sectional and cohort studies can provide reliable 
evidence (15). Therefore, cross-sectional and cohort studies of diagnostic accuracy were 
initially categorized as high quality. The evidence was down-rated based on the presence 
of (i) risk of bias; (ii) inconsistency or heterogeneity; (iii) indirectness (addressing a different 
population than the one under consideration); or (iv) imprecision. Based on the rating of 
the available evidence, the quality of evidence was categorized as high, moderate, low, or 
very low.
Table 2. GRADE categories of the quality of evidence
Level of 
evidence Definition
High Further research is very unlikely to change our confidence in the estimate of effect
Moderate Further research is likely to have an important impact on our confidence in the effect
Low Further research is very likely to have an estimate of effect and is likely to change 
the estimate
Very low Any estimate of effect is very uncertain
9. Values, preferences and ethical considerations
Values and preferences can be an important consideration for informing clinical and public 
health recommendations. Therefore, searches of the published literature on values and 
preferences were conducted and an online survey was conducted. The survey was carried 
out in November 2017 with the support of the Panel of Women and Men Affected by 
Leprosy of ILEP. The face-to-face group discussions were conducted in persons affected 
by the disease, using standard questions regarding perceptions related to challenges for 
diagnosis, treatment and contact screening; suggestions were solicited for improvements in 
the provision of these services. The goal was to provide insight into the patient’s perspective, 
identify hidden barriers or concerns with regard to diagnostic and treatment options for 
leprosy and receive suggestions to facilitate implementation of services in these core leprosy 
control areas. To ensure a diversity of viewpoints among persons affected by leprosy, surveys 
were conducted in four different countries (Colombia, Ghana, India and Nepal), targeted 
both men and women, patients with both PB and MB leprosy, and persons from different 
age groups. The tool used for the focus group discussion is provided in Annex 3.
A total of 70 persons affected by leprosy participated in focus group discussions. 
Participants included held 3 children, 36 women and 34 men. With regard to diagnosis of 
leprosy, all four groups reported stigma and lack of involvement of persons affected, and 
health systems issues (long distance to reach a health centre, unavailability of trained staff, 
non-inclusion of leprosy in doctors’ and nurses’ training curricula) as barriers.
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With regard to treatment, all groups reported barriers related to the health system 
(availability of drugs and registers to start the treatment, short opening hours, distance of 
the treating centre from home). The groups from Colombia, Ghana and Nepal mentioned 
lack of proper counselling about the long-term nature of the treatment, as well as a lack of 
proper explanation of the side-effects of skin discoloration due to clofazimine as a possible 
cause of interruption of treatment. This was not reported by the group from India, which 
reported stigmatization and unfriendly care by the health-care workers as important barriers.
With regard to preventive treatment (chemoprophylaxis) and potential issues related 
to screening of contacts of leprosy patients, the groups from Ghana and Nepal reported 
no potential stigma-related problems; rather they suggested how to conduct it more easily 
through the involvement of persons with the disease and through camps, to facilitate access 
by the relatives of the patients. They also suggested providing health education to the general 
community and to community leaders, while providing chemoprophylaxis. The group from 
Colombia reported the problem of stigmatization and “a sense of guilt” for the patients, 
if the contact screening is not preceded by community education and proper counselling 
of patients. They also suggested a broader screening intervention to cover social contacts, 
not only family members, after proper counselling and provision of information about 
the activity. All groups suggested proper counselling of the target populations, along with 
ensuring the availability of treatment delivery “on the spot” right after the home screening. 
As an alternative, the group from Ghana suggested preventive treatment as part of mass 
drug administration (MDA) for lymphatic filariasis since MDA campaigns are done annually 
in their country through door-to-door campaigns.
In terms of safeguarding the guideline development process for a disease often 
associated with stigma, the Secretariat ensured that a representative from an association of 
persons affected by leprosy was member of the GDG, to provide insight into the potential 
impact of recommendations on patients. The GDG also considered possible human rights 
impacts. As per the UN Principles and Guidelines for the elimination of discrimination 
against persons affected by leprosy and their family members (17), important human rights 
considerations such as effects on family life, employment, education and health care were 
considered. Two WHO staff (experts in human rights and gender) were included as part of the 
Steering Group; they reviewed the planning document and related PICO questions and the 
draft guidelines. In addition, four ERG members were persons affected by the disease (ILEP 
Panel) and two members were international experts in the field of stigma and discrimination 
related to communicable diseases (TB, HIV or NTDs, including leprosy).
10. Formulation of recommendations
The GDG, with the support of the Steering Group, formulated recommendations based on 
the evidence summarized in the systematic reviews on diagnostic accuracy and potential 
benefits and harms, and other factors, such as effects on service delivery, feasibility, 
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acceptability, cost–effectiveness and values and preferences of end users. The strength of 
each recommendation was graded as “strong” or “conditional”.
The strength of a recommendation reflects the extent to which GDG was confident that 
the desirable effects of following a recommendation outweigh the potential undesirable effects. 
The strength is influenced by the following factors: the quality of the evidence, the balance 
of benefits and harms, values and preferences, and resource implications. Other factors 
that impact the strength of recommendations include effects on equity and human rights, 
acceptability and feasibility. A strong recommendation is one for which GDG was confident 
that the desirable effects of adhering to the recommendation outweigh the undesirable 
effects, there is confidence in the estimates of effect, the recommended action is acceptable 
to patients and promotes equity, the benefits are worth the costs, and the recommended 
action is feasible for implementation. A conditional recommendation is one for which GDG 
concluded that the desirable effects of adhering to the recommendation probably outweigh 
the undesirable effects, but the balance of benefits to harms was relatively small or there 
was less certainty about the conclusions. The implications of a conditional recommendation 
are that, although most programmes or settings would adopt the recommendation, some 
would not or would do so only under certain conditions. Reasons for making a conditional 
recommendation include the absence of high-quality evidence, imprecision in outcome 
estimates, uncertainty regarding patient preferences and how individuals value the outcomes, 
small benefits relative to harms, and benefits that may not be worth the costs (including the 
costs of implementing the recommendation).
The GDG discussed and agreed upon the proposed wording of the recommendations, 
with attention to using non-stigmatizing language. The recommendations incorporate human 
rights considerations as specified in the UN Principles and Guidelines for the elimination 
of discrimination against persons affected by leprosy and their family members, including 
special considerations for women, children or other vulnerable populations (17).
All decisions were reached after thorough discussion of the proposed recommendations, 
including their strengths and, as needed, the conditions to be attached to the recommendations. 
Disagreements were discussed and resolved through review of the evidence and an informal 
consensus process facilitated by the Chair and Co-chair (methodologist) at the face-to-face 
meeting. Evidence-to-recommendation tables were formulated during the GDG meeting, 
with only minor editorial changes made subsequently (Annex 2). They were circulated to all 
GDG members for their endorsement and finalization. A draft of the guidelines was provided 
to GDG members during the consultation with the ERG and all GDG members approved 
the final version before submission to the GRC.
Although vaccinations could prevent leprosy, WHO regulations require that SAGE 
formulate all recommendations on vaccination (immunoprophylaxis). Therefore, the 
GDG reviewed evidence on vaccinations but did not formulate recommendations; rather, 
findings on vaccinations were shared with the SAGE BCG working group to help inform its 
recommendations.
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Part II: Recommendations
1. Diagnosis
1.1 Diagnosis of leprosy disease
Recommendation
It is recommended to base the diagnosis of leprosy on the following: clinical examination, 
with or without slit-skin smears or pathological examination of biopsies (conditional 
recommendation, very low quality evidence).
Rationale
The diagnosis of leprosy in current practice is based on the presence of at least one of the 
three cardinal signs (5): (i) definite loss of sensation in a pale (hypopigmented) or reddish skin 
patch; (ii) thickened or enlarged peripheral nerve with loss of sensation and/or weakness of 
the muscles supplied by that nerve; or (iii) presence of acid-fast bacilli in a slit-skin smear. 
The slit-skin smear requires technical expertise in taking the smear, fixation and staining, and 
reading the results (18). Slit-skin smears are positive only in MB leprosy (i.e. any positive slit-
skin smear is classified as MB irrespective of the number of patches and/or nerve involvement). 
The early clinical stages of leprosy and milder forms of leprosy (PB leprosy) are diagnostically 
the most challenging. The ELISA and lateral flow assays show low accuracy for PB leprosy. 
Although PCR-based assays using tissue specimens show higher sensitivity and specificity 
than ELISA and lateral flow assays, they would be difficult to perform in most field settings. 
PCR assays lack standardization, currently no PCR tests are commercially available, and they 
require technical and laboratory expertise. Although PCR-based assays using urine and blood 
samples are a less invasive potential alternative to skin smears and pathological examination 
of biopsy, studies indicate low sensitivity.
Summary of the evidence
Studies of the most commonly used ELISA and lateral flow tests show low sensitivity for 
PB leprosy, which is often harder to diagnose clinically than MB leprosy (19–41). Based on 
estimated median sensitivities and specificities, negative tests are not that useful for ruling 
out PB leprosy and some patients with PB leprosy would be missed. Effects of missed or 
delayed diagnosis of PB leprosy are not known. Although some tertiary-level centres and 
highly specialized research centres can perform PCR to detect DNA of M. leprae on slit-skin 
smear or biopsy specimens, the tests that showed highest sensitivity and specificity (43–49) 
lack standardization and are not commercially available. In addition, studies showing higher 
accuracy of PCR used slit-skin smear or biopsy specimens rather than less invasive sampling 
techniques, e.g. blood or urine, for which sensitivity of PCR is low (46,47).
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Therefore, based on currently available evidence, newer ELISA, lateral flow and PCR 
tests do not represent a clear advantage over current standard diagnostic methods (clinical 
diagnosis with or without confirmatory tests such as slit-skin smear or biopsy).
No study of alternative tools for diagnosis of leprosy, such as ultrasound of the peripheral 
nerves, met inclusion criteria. Several publications support the use of ultrasound to diagnose 
leprosy-associated neuritis in persons known to have leprosy (50–59).
1.2 Diagnosis of leprosy infection among asymptomatic contacts
Recommendation
There is no test that the GDG recommends to diagnose leprosy infection (latent leprosy) 
among asymptomatic contacts (conditional recommendation, low quality evidence).
Rationale
Evaluation of potential tests for M. leprae infection requires longitudinal follow-up to 
determine the incidence of clinical leprosy, to determine the predictive utility of the tests. 
Leprosy has a long incubation period (measured in years) between infection with M. leprae 
to the manifestation of signs and symptoms. It is assumed that there is a subclinical/latent 
infection stage after infection with M. leprae, which may subsequently lead to overt signs and 
symptoms of leprosy. A test to identify such latent infection would be useful for identifying 
persons who could benefit from preventive interventions. However, a systematic review on 
the predictive utility of tests for diagnosing latent leprosy found that many did not report 
long-term follow up, and among studies with some years of follow up, accuracy was poor 
for identifying persons who will develop leprosy (42). Therefore, the GDG determined 
that presently available tests to identify contacts who have been infected by M. leprae are 
insufficiently accurate to recommend their use.
Summary of the evidence
In a review of seven studies on tests to detect leprosy infection among asymptomatic contacts 
with at least 1 year of follow up, relatively few people with positive tests go on to develop 
clinical leprosy, with an overall PPV of only 4% (42).
2. Treatment for leprosy
2.1 Treatment regimens and duration of treatment for PB and MB leprosy
Recommendation
The GDG recommends the same 3-drug regimen with rifampicin, dapsone and clofazimine 
for all leprosy patients, with a duration of treatment of 6 months for PB leprosy and of 12 
months for MB leprosy (conditional recommendation, very low-quality evidence).
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Rationale
The currently recommended MDT for PB leprosy is rifampicin and dapsone for 6 months and 
the currently recommended MDT for MB leprosy is rifampicin, clofazimine and dapsone for 
12 months. MDT is distributed in blister packs at the point of use (provided free-of-cost as 
a donation by a pharmaceutical company and distributed to national leprosy programmes 
by WHO) with specific packs for adults and children. The regimens require all patients 
with leprosy to be classified as either PB or MB, with further distinction between adults and 
children. Four different blister packs are available: PB adult, PB child, MB adult and MB child. 
The PICO question focused on benefits and harms of using the same 3-drug regimen with 
the same duration of treatment (6 months) for all leprosy patients (UMDT) compared with 
the currently recommended MDT regimens for PB and MB leprosy. Potential advantages of 
such an approach are simplification of the treatment regimen, reduced duration of treatment 
for patients with MB leprosy, reduced impact of misclassification of leprosy cases (persons 
with MB leprosy incorrectly classified as PB leprosy would receive three drugs with UMDT 
rather than two drugs with standard PB-MDT) and simplified logistics since only two types 
of blister packs of drugs (adult and child) would be required.
The GDG determined that a recommendation to use a 3-drug regimen for PB leprosy 
is justified, based on evidence showing potential benefits of a 3-drug over a 2-drug regimen 
for PB leprosy (10–14 more patients for 100 patients treated with a 3-drug regimen estimated 
to have a good clinical outcome after 12 months, and 26 more patients for 100 patients after 
24 months); some evidence suggests a potential increase in risk of relapse in PB patients 
with the currently recommended 2-drug regimen. The 3-drug regimen has the potential to 
reduce the consequences of misclassification of MB patients as PB patients (based on lesion 
counts), and implementation advantages of using the same 3-drug combination for both MB 
and PB leprosy (Table 3). This is a conditional recommendation based on very low quality 
evidence, indicating that in persons with PB leprosy who are very concerned about the 
potential skin discoloration due to clofazimine, an alternative regimen (i.e. 2-drug therapy) 
could be considered. For MB leprosy, the GDG determined that there is not enough evidence 
of equivalent outcomes to support a recommendation to shorten the duration of treatment. 
Furthermore, the only available RCT found a potential increase in relapse rate with a shorter 
duration of treatment; the potential negative effects of a shorter duration of treatment on 
clinical outcomes and lack of evidence of benefits outweighed patient preferences for a 
shorter duration of treatment and considerations related to lower costs.
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Table 3. Recommended treatment regimens
Age group Drug Dosage and frequency
Duration
MB PB
Adult Rifampicin 600 mg once a month 12 months 6 months
Clofazimine 300 mg once a month and 50 mg 
daily
Dapsone 100 mg daily
Children 
(10–14 years)
Rifampicin 450 mg once a month 12 months 6 months
Clofazimine 150 mg once a month, 50 mg daily
Dapsone 50 mg daily
Children <10 
years old or 
<40 kg
Rifampicin 10 mg/kg once month 12 months 6 months
Clofazimine 6 mg/kg once a month and 1 mg/kg 
daily
Dapsone 2 mg/kg daily
Note: The treatment for children with body weight below 40 kg requires single formulation medications since no MDT combination 
blister packs are available. For children between 20 and 40 kg, it would be possible to follow the instructions of the Operational 
Manual, Global Leprosy Strategy 2016–2020 on how to partly use (MB-Child) blister packs for treatment (60).
Summary of the evidence
The evidence review identified a number of studies (61–65) of UMDT (rifampicin, clofazimine 
and dapsone for 6 months for both PB and MB leprosy). This regimen includes two changes 
from the current recommended MDT regimens; PB patients receive three drugs as opposed 
to two with the addition of clofazimine and MB patients receive the same regimen but the 
duration is reduced from 12 to 6 months. A number of controlled and several uncontrolled 
studies were included in the evidence review (63,64,66–68).
For PB leprosy patients, there is evidence of better clinical outcomes with a 3-drug 
6-month regimen compared with a 2-drug 6-month regimen (63–68). The difference in 
likelihood of a good clinical outcome or marked improvement was 10% and 14% at 12 
months and 26% at 24 months (66–68). Evidence on risk of relapse of different regimens for 
PB leprosy was limited to an indirect analysis that found a higher relapse rate after treatment 
in PB patients using a shorter 2-drug regimen compared to the relapse rate in persons with 
MB leprosy using a longer 3-drug regimen (69). Although this comparison involves persons 
with different types of leprosy, the relapse rate should be lower with PB than MB leprosy. 
Another consideration is some misclassification of persons with MB leprosy as PB leprosy is 
defined by lesion counts, which could lead to under-treatment with a 2-drug PB regimen. 
This under-treatment could be partly mitigated by the current recommendation to use a 
3-drug regimen for PB leprosy. No study reported adverse events with clofazimine and 
compliance was similar among PB patients taking three drugs and those taking two drugs, 
despite concerns regarding skin discoloration with clofazimine.
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For MB leprosy patients, evidence on potential benefits and harms of a shorter 3-drug 
6-month regimen compared with a 3-drug 12-month regimen were limited and inconclusive 
(63–65). Recently published results of an RCT found a 3-drug 6-month regimen associated 
with an increased risk of relapse (2.2% vs 0.3%, relative risk (RR) 6.3, 95% confidence interval 
(CI): 0.78–61), though the difference was not statistically significant and the estimate was 
imprecise (65). The trial found no difference in the risk of leprosy reactions, rate of decrease 
in bacillary index or likelihood of disability progression beyond already affected limbs. A 
large non-randomized study reported zero relapses (64). Another study found a 6-month 
regimen associated with a trend towards worse clinical outcomes compared with a 12-month 
regimen (good clinical response at 24 months 25% vs 77%, RR 0.33, 95% CI: 0.06–1.8) 
(63). Several uncontrolled studies were included in the evidence review, but provided very 
limited data on relapses and clinical outcomes (61,70,71). Results regarding side-effects of 
and compliance with a shorter MB leprosy regimen seem to be encouraging, though data 
were scarce.
The GDG concluded that changing to a 3-drug regimen with a duration of 6 months for 
PB leprosy might be associated with improved clinical outcomes and potential advantages 
with regard to implementation in the field. For MB leprosy, there was insufficient evidence 
to recommend a decrease in the duration of the current 3-drug regimen for MB leprosy from 
12 to 6 months. In addition, the only available RCT found a potential association between 
shorter duration of treatment for MB leprosy and increased risk of relapse.
Remarks
Pharmacovigilance after the introduction of the new 3-drug regimen for PB leprosy is needed 
to ensure monitoring of adverse events. Treatment completion rates will have to be carefully 
monitored since studies supported by Netherlands Leprosy Relief (www.leprosy-information.
org) indicate stigma associated with skin discoloration as a side-effect of the medications, 
despite the similar compliance seen with 3-drug versus 2-drug regimens (61,65). In focus 
groups, persons affected by leprosy pointed out the need for (i) adequate health education of 
patients including information about side-effects such as skin discoloration and (ii) monitoring 
of treatment adherence.
2.2. Treatment for drug-resistant leprosy
Recommendation
The GDG recommends for leprosy patients with rifampicin resistance to be treated using 
at least two of the following second-line drugs: clarithromycin, minocycline, or a quinolone 
(ofloxacin, levofloxacin or moxifloxacin), plus clofazimine daily for 6 months, followed by 
clofazimine plus one of the second-line drugs daily for an additional 18 months.
In case of rifampicin plus ofloxacin resistance, a quinolone should not be chosen; 
therefore, the recommended regimen is clarithromycin, minocycline and clofazimine for 
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6 months followed by clarithromycin or minocycline plus clofazimine for an additional 18 
months (conditional recommendation, based on expert opinion; no evidence retrieved).
Rationale
The number of leprosy patients tested for resistance globally is too small to allow for accurate 
estimates of drug resistance. However, several high-burden countries have reported cases 
of drug resistance among new and previously treated patients (10,11). Five studies reported 
prevalence of rifampicin resistance, estimated at 1.4% in new cases and 8% in relapsed 
patients (72–76). Cases with resistance to quinolones have also been detected. In India, 
the number of cases of quinolone resistance appears to equal the number of cases of 
dapsone resistance, highlighting the need to limit the use of quinolones to persons with clear 
indications. Recommendations on second-line treatments are needed to guide management 
of resistant leprosy. Because evidence on effectiveness of regimens to treat drug-resistant 
leprosy is lacking, recommendations are based on expert opinions, resistance patterns, and 
known activity of antibacterial alternatives.
Patients who start MDT and are found to have resistance to rifampicin alone or in 
association with resistance to dapsone, shall re-start a full course of second-line treatment, 
regardless of clinical outcomes with MDT. Recommended regimens for drug-resistant leprosy 
are given in Table 4:
Table 4. Recommended regimens for drug-resistant leprosy
Resistance type
Treatment
First 6 months (daily) Next 18 months (daily)
Rifampicin resistance Ofloxacin 400 mg* + 
minocycline 100 mg + 
clofazimine 50 mg
Ofloxacin 400 mg* OR 
minocycline 100 mg + 
clofazimine 50 mg
Ofloxacin 400 mg* + 
clarithromycin 500 mg + 
clofazimine 50 mg
Ofloxacin 400 mg* + clofazimine 
50 mg
Rifampicin and ofloxacin 
resistance
Clarithromycin 500 mg 
+ minocycline 100 mg + 
clofazimine 50 mg
Clarithromycin 500 mg 
OR minocycline 100 mg + 
clofazimine 50 mg
*Ofloxacin 400 mg can be replaced by levofloxacin 500 mg OR moxifloxacin 400 mg
Summary of the evidence
The evidence review found no studies meeting inclusion criteria on the effectiveness of 
regimens for rifampicin-resistant leprosy. Rifampicin is considered the most important drug 
in standard MDT. Several widely available drugs that are not part of standard MDT are 
known to have effects against M. leprae (77) and can be incorporated into an alternative 
second-line regimen for rifampicin-resistant leprosy. Treatment should consist of at least two 
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second-line drugs (clarithromycin, minocycline or a quinolone) plus clofazimine daily for 
6 months, then clofazimine plus one of these drugs daily for an additional 18 months. In 
case of associated ofloxacin resistance, a fluoroquinolone should not be used as part of the 
second-line treatment regimen.
Because fluoroquinolones are active against TB, leprosy patients starting a second-line 
regimen should be investigated for signs and symptoms of TB, to ensure that persons with TB 
are treated with an appropriate regimen effective against both diseases, to avoid emergence 
of drug-resistant TB. Pharmacovigilance of recommended regimens for resistant leprosy is 
needed to determine adverse events. This includes electrocardiographic monitoring, due to 
the risk of QT interval prolongation and associated cardiac arrhythmia, which is associated 
with exposure to clarithromycin as well as minocycline and quinolones.
Patients treated for resistant leprosy should be registered and their treatment outcomes 
closely monitored and reported to national authorities and to WHO, to better inform future 
recommendations on optimal treatment strategies and outcomes for drug-resistant leprosy.
3.  Prophylaxis
3.1. Prevention of leprosy through chemoprophylaxis
Recommendation
The GDG recommends the use of SDR as preventive treatment for contacts of leprosy 
patients (adults and children 2 years of age and above), after excluding leprosy and TB 
disease, and in the absence of other contraindications. This intervention shall be implemented 
by programmes that can ensure: (i) adequate management of contacts and (ii) consent of 
the index case to disclose his/her disease (conditional recommendation, moderate quality 
evidence).
Rationale
Leprosy is associated with important clinical and social consequences. Prevention of leprosy 
would be preferable to treating patients after clinical presentation and would provide 
additional public health benefits in terms of reducing the spread of the disease. An RCT 
found SDR effective at reducing risk of leprosy over 5–6 years in leprosy contacts. For every 
1000 contacts treated with SDR, there were four leprosy cases prevented after 1–2 years 
and three cases prevented after 5–6 years. Recommended dosage schedules for SDR are 
given in Table 5.
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Table 5. Rifampicin dose for single-dose rifampicin (SDR)
Age/weight Rifampicin single dose
15 years and above 600 mg
10–14 years 450 mg
Children 6–9 years (weight ≥20 kg) 300 mg
Children <20 kg (≥2 years) 10–15 mg/kg
Summary of the evidence
The possibility of using one of the medications of MDT to prevent leprosy among contacts 
has been studied extensively, with a systematic review finding that dapsone for prolonged 
periods could prevent the occurrence of leprosy in contacts (78). The latest studies focused 
on the effect of SDR. A double-blind RCT (COLEP study) found SDR in leprosy contacts 
associated with a reduction in risk of leprosy of 57% over 2 years and of 30% over 5–6 years 
(79). For every 1000 contacts treated with SDR, there were four leprosy cases prevented after 
1–2 years and three cases prevented after 5–6 years. The protective effect of SDR occurred 
in the first 2 years, with no additional effect after 4 and 6 years (80). However, the total 
impact of the intervention remained statistically significant after 6 years. One analysis based 
on COLEP found that SDR was cost effective, with an incremental cost–effectiveness ratio of 
US$ 158 per additional prevented leprosy case (13). A sub-study of the COLEP RCT showed 
that BCG at birth appears to potentiate the protective effect of SDR in contacts from 57% 
to 80% (84). A recent systematic review did not identify any additional controlled data on 
effectiveness of SDR (82), though a trial of combined post-exposure chemoprophylaxis and 
immunoprophylaxis is currently in progress (83). A published expert meeting report found 
that SDR does not increase the risk of rifampicin-resistant M. tuberculosis (85). Nonetheless, 
the GDG determined that it would be prudent to exclude TB before administering SDR to 
consenting contacts. More studies are needed to assess the efficacy of repeated SDR on 
long-term outcomes, since COLEP found that efficacy of SDR was higher at 2 years than 
after 5–6 years.
The impact of chemoprophylaxis is likely to be higher as the definition of contacts is 
expanded (e.g. from household contacts only to all contacts in a community). However, a 
broader definition would perhaps increase the costs/effort associated with screening, become 
less efficient according to the extent that it includes persons at lower risk of developing 
leprosy, and require even greater caution to prevent stigma. The GDG suggests that in areas 
of high endemicity and concomitant high population density a “blanket” approach of SDR 
for the whole community could be considered, although there is only one study showing 
efficacy of such an approach (86).
The GDG concluded that the evidence supports a recommendation to use SDR in 
contacts of leprosy patients to prevent leprosy. Although the COLEP trial was conducted in 
one country, preliminary reports from the multicountry Leprosy Post-Exposure Prophylaxis 
(LPEP) study (81) are encouraging with regard to feasibility and acceptability in other settings 
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(unpublished data). Because leprosy is a highly stigmatized disease, caution must be exercised 
when implementing SDR in contacts, particularly for contacts outside the family of the patient. 
Programmes must respect the wish of patients to disclose or not disclose their diagnosis 
to contacts. When patients do not authorize disclosure, the GDG does not recommend 
identification or screening of contacts or prescribing preventive treatment to contacts. The 
blanket approach might be more feasible in a context of high stigma and discrimination; 
under this approach disclosure of index cases may not be required.
Remarks
The GDG concluded that the availability of an effective and simple (single dose) preventive 
treatment is likely to improve the quality and completeness of contact screening and 
treatment. However, implementation of the recommendation is conditional on two key 
factors: (i) adequate management of contact screening and (ii) assurance of obtaining 
patient consent before contact screening. The effectiveness of SDR for preventing leprosy is 
likely to require programmes to ensure high coverage of contact screening and use a broad 
definition for contacts, including social contacts. In addition, programmes need to employ 
mechanisms to ensure that patient consent is obtained appropriately and that contact tracing 
is not performed without patient consent, given the potential trade-offs between prevention 
of leprosy and harmful effects related to stigma, which could worsen inequities. Therefore, 
programmes and clinicians must adhere to patient preferences regarding disclosure of leprosy 
diagnosis. National guidelines on SDR should include clear guidance on how to obtain consent 
from the index case for identification and examination of contacts. Of critical importance is 
the need for efforts to minimize leprosy-related stigma in the community, so that the burden 
of actual and anticipated stigma does not promote withholding consent for SDR prophylaxis 
where it is otherwise recommended, and minimize situations in which patients and health-
care workers face an “ethical dilemma” of either exposing and potentially stigmatizing the 
patient by treating contacts, or denying effective prophylaxis for an at-risk contact.
3.2. Prevention of leprosy through immunoprophylaxis (vaccines)
WHO regulations require that SAGE formulate all vaccination (immunoprophylaxis) 
recommendations. Therefore, the GDG reviewed evidence on vaccinations but did not 
formulate recommendations; rather, findings on vaccinations were shared with the SAGE 
BCG working group to help inform its recommendations.
Rationale
Vaccines are a core intervention to prevent and reduce the burden and impact of 
communicable diseases on population health. Evidence on the efficacy of BCG to prevent 
leprosy is well established (87,88), but there have been no WHO recommendations for its 
use as a leprosy preventive tool before the start of this guideline development process. BCG is 
widely available and already part of the vaccination policy in most leprosy-endemic countries.
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Summary of the evidence
A systematic review found BCG vaccination at birth effective at reducing risk of leprosy 
(pooled reduction in risk 55%), though the magnitude of the effect varied (87). Most studies 
were conducted in high-burden countries. Evidence indicates that several vaccination 
interventions apart from BCG show similar or slightly lower efficacy compared to BCG for 
reducing the risk of leprosy (87–90). These vaccines are killed myobacteria, as opposed to 
BCG, which is a live vaccine; however, only one, the M. indicum pranii vaccine (formerly 
known as M. w), is currently produced.
Two large RCTs (91,92) of BCG revaccination compared with BCG only given at birth 
were not included in the latest review on BCG and leprosy (87). The first trial showed almost 
identical leprosy rates in both groups while in the other trial BCG revaccination was associated 
with a 49% reduction in risk of leprosy versus placebo. Therefore, the effectiveness of BCG 
revaccination is unclear. An analysis of data from the COLEP SDR trial also found that BCG at 
birth seems to potentiate the effect of SDR given as chemoprophylaxis in contacts of persons 
with leprosy (86). An ongoing RCT is studying the effect of BCG revaccination among a large 
cohort of contacts of persons with leprosy (83).
Conclusions shared with SAGE
 • BCG at birth is effective at reducing the risk of leprosy; therefore, its use should be 
maintained at least in all leprosy high-burden countries or settings (good quality 
of evidence).
 • BCG at birth appears to potentiate the protective effect of SDR in contacts from 
57% to 80% (low quality of evidence).
 • The effectiveness of BCG revaccination (second dose of BCG following a birth dose) 
is unclear, since two large trials on BCG revaccination showed conflicting results.
 • Evidence indicates the efficacy (based on two RCTs) of M. indicum pranii in 
preventing leprosy (moderate quality of evidence).
The revised policy for BCG in the prevention of both TB and leprosy was released 
through a WHO position paper in February 2018 (93), which summarizes the BCG-related 
conclusions of the GDG of these guidelines.
4. Implementation and evaluation
With regard to implementation and evaluation of the guidelines, the GLP will work closely with 
WHO regional and country offices and implementing partners to ensure wide dissemination 
through regional and subregional events. WHO staff will provide telephone, email and direct 
assistance to country programme officers adapting the guidelines. Opportunities to discuss 
the implementation of the guidelines with country staff will be sought during planned country 
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visits. Regional dissemination workshops for the adaptation of the guidelines will be organized 
if resources permit. The GLP will also disseminate the guidelines through its collaboration 
with the ILEP Technical Commission and the ILEP network of country coordinators.
There will be an evaluation by the WHO Steering Group during the first year of 
implementation of the guidelines, focusing on their accessibility and acceptability. As an 
assessment of document uptake, the number of downloads of the document from the WHO 
websites will be monitored, as well as the number of hard copies of the guidance requested 
and distributed. After implementation, an evaluation of the impact of the guidelines will be 
undertaken through review of epidemiological data, following an assessment of the uptake 
of the recommendations and barriers to effective implementation.
WHO plans to monitor the impact of the guidelines on health outcomes. Following 
the recommended change in the PB leprosy regimen, WHO will monitor the proportion 
of treatment completers to evaluate effects on treatment compliance. The impact of the 
recommendation on preventive treatment with SDR will be monitored through assessment of 
disease trends and through analysis of disease incidence in leprosy contacts. This information 
is already requested by WHO through the annual leprosy data collection online tool (in use 
since 2016).
5. Updating
These guidelines are assumed to be valid until at least 2022, unless there is the emergence 
of significant new evidence that would require a review before that date.
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Part III: Research priorities
1. Leprosy diagnosis
Tests with promising results for higher diagnostic accuracy (e.g. PCR tests using tissue samples) 
should be assessed in larger, well-designed studies using assays that are standardized and 
feasible for use in field settings. Such studies should also evaluate their accuracy for predicting 
the development of leprosy in contacts. In addition, research is needed on the diagnostic 
utility of other tools, including ultrasound and other imaging tests, as possible aids to diagnosis.
New biomarkers are needed to identify persons with leprosy. Tests for these should 
be more accurate than previously evaluated ELISA and lateral flow tests. A test protocol 
study reported the utility of mixed assays that detect cell-mediated responses (cytokines 
and chemokines) as well as M. leprae-specific antibodies to detect both PB and MB leprosy 
(94). More studies are needed to determine the use of identified biomarkers for diagnosis. 
Longitudinal studies are needed to assess how well these tests predict the development of 
overt leprosy in contacts of persons with leprosy.
2. Leprosy treatment
Adequately powered, appropriately designed studies are needed on the benefits and harms 
of shorter MDT regimens for MB leprosy, including effects on bacteriological outcomes 
(e.g. tests of M. leprae viability in skin and nerves). For both PB and MB leprosy, more well-
conducted studies are needed to better understand optimal treatment strategies.
Treatment for drug-resistant leprosy
The GDG emphasizes the need to enhance current antimicrobial resistance surveillance for 
leprosy. Given the small numbers of detected leprosy resistance, an RCT on the efficacy of 
different second-line regimens is unlikely to be feasible. However, observational studies that 
employ systematic methods to collect clinical and bacteriological outcomes of treatment 
for resistant M. leprae would be useful for understanding potential benefits and harms of 
alternative strategies.
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3. Prevention of leprosy
3.1 Prevention of leprosy through chemoprophylaxis
Studies that evaluate the effectiveness of alternatives to SDR for chemoprophylaxis (e.g. 
regimens that use drugs other than rifampicin or multiple doses) are needed. In addition, 
research is needed to understand the effectiveness of chemoprophylaxis provided through 
a “blanket/high-risk population” approach rather than through identification of contacts, 
since the former might increase feasibility and reduce the risk of stigma compared to contact 
tracing-based approaches.
3.2 Prevention of leprosy through vaccines
Trials are needed on new and existing vaccines, including studies on LepVax, a new subunit 
vaccine currently in stage 1a studies. Trials are also needed on the effects of combined post-
exposure immunoprophylaxis and chemoprophylaxis. The GDG recommends that any new 
TB vaccine be evaluated for the prevention of other mycobacterial diseases such as leprosy 
and Buruli ulcer and vice versa.
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Annex 2: Evidence-to-
recommendation tables
Question 1a: Is there a diagnostic test for the diagnosis of leprosy disease 
(PB and/or MB) that has sufficient sensitivity and specificity and whose use is 
feasible under programmatic conditions?
Population: Adults and children with suspected 
leprosy and leprosy patients and 
controls
Background:
Since 1996, WHO recommended diagnosis 
of leprosy based on at least one of three 
cardinal signs: (i) hypopigmented skin patch 
with loss or reduced sensation; (ii) enlarged 
nerve; (iii) slit-skin smear positive for leprosy 
bacilli. However, several studies on leprosy 
diagnostics, including on blood/serum 
samples have been carried out. Presently, 
confirmatory tests for leprosy (microscopy on 
slit-skin smears and biopsy) are usually carried 
out only in referral centres.
Intervention: ELISA tests
Antibodies to PGL-1, MMP-I and -II, 
NDO-LID
Immunochromatographic/lateral flow 
tests
PCR
Combined antibody/cytokine and/or 
chemokine tests
Comparison: Clinical diagnosis based on the three 
cardinal signs and/or slit-skin smear or 
biopsy
Main outcomes: Sensitivity/specificity
Setting: All settings (low- and high-burden); 
developing countries
Perspective: Clinic/field
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Assessment
Judgement Research evidence Additional consideration
Pr
ob
le
m
Is the problem 
a priority?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
A diagnostic test for leprosy, especially one able to 
detect the disease in its early stages, could be key for 
an early diagnosis and for reducing transmission. This 
would be important with the burden of the disease 
reducing and prospective decline in experience among 
physicians in dealing with the disease. 
D
es
ir
ab
le
 e
ff
ec
ts
How 
substantial are 
the desirable 
anticipated 
effects?
  Trivial
  Small
  Moderate
  Large
  Varies
  Don't know
Desirable anticipated effects:
Some studies show good sensitivity for both MB and 
PB leprosy; however, they are very small studies with 
high imprecision and methodological limitations. Most 
assays showing higher sensitivity for PB leprosy are 
complicated to perform at the primary health-care level 
where the majority of patients are diagnosed.
We don't know the effect on patient outcomes of using 
a diagnostic test compared to standard methods to 
detect early leprosy.
The GDG determined that 
the evidence shows that 
no test is available that 
shows sufficient sensitivity 
and specificity, especially 
for diagnosing PB leprosy. 
A desirable feature of a 
new diagnostic test would 
be one that uses a less 
invasive sample than skin 
smear or biopsy. It is noted 
that PCR on skin biopsy 
specimens shows relatively 
higher sensitivity and very 
high specificity, but based 
on the low level of the 
quality of evidence along 
with technical complexity 
with current tools, and 
the lack of a commercial/
clinically available test, it is 
not feasible for use outside 
referral or research centres.
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Judgement Research evidence Additional consideration
U
nd
es
ir
ab
le
 e
ff
ec
ts
How 
substantial 
are the 
undesirable 
anticipated 
effects?
  Large
  Moderate
  Small
  Trivial
  Varies
  Don't know
Undesirable anticipated effects:
Direct harms are likely to be very low given the nature 
of the tests (simple blood tests) but there are no direct 
data. Further, undesirable anticipated effects relate 
to false-positive and false-negative results leading to 
incorrect and missed diagnoses.
Studies of the most commonly investigated ELISA and 
lateral flow tests show low sensitivity for PB leprosy. 
Negative tests are not that useful for ruling out PB 
leprosy. Effects of missed or delayed diagnosis of PB 
leprosy are not known. 
Summary of findings:
Condition 
(accuracy 
measure)
Estimate Quality
ELISA for anti-PGL
Sens: MB Median 76% 
(17–98)
Very low
Sens: PB Median 24% 
(0–70)
Very low
Spec: 83–96% Very low to 
low
ELISA for anti-MMP-I
Sens: MB 74% (46–86%) Very low
Sens: PB 22% (7.3–55%) Low
Spec: 87–100% Very low
ELISA for anti-MMP-II
Sens: MB Median 82% 
(70–98)
Very low
Sens: PB Median 48% 
(39–62%)
Low
Spec: 14–100% Very low to 
low
NDO LID lateral flow
Sens: MB 87–96% Low
Sens: PB 20% and 32% Very low
Spec: 75–98% Very low to 
low
ML flow
Sens: MB 84% (87–90%) Low
Sens: PB 30% (0–38%) Low
Spec: 86–100% Very low to 
low
PCR : biopsy
Sens: MB 42–100% Very low
Sens: PB 50–75% Very low
Spec: 73–100% Very low
Single or few studies of 
ELISA for 45-kDa antigen, 
LID-1, PGL-1/LID-1 (rapid 
ELISA); lateral flow tests 
(MMP-1, SD Leprosy and 
On Site Leprosy AB Rapid 
Test); PCR tests using whole 
blood or nasal secretions; 
sum of errors (SOE) for all 
very low.
Predictive values for ELISA 
for MMP-II similar to ELISA 
for anti-PGL-I and not 
shown here.
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Pre-test 
disease 
probability
PPV
Probability of 
leprosy with a 
negative test
(1-NPV)
ELISA for anti-PGL-I
MB 1% 10% 0.25%
MB 10% 55% 3%
MB 20% 73% 6%
PB 1% 4% 0.80%
PB 10% 29% 8%
PB 20% 48% 16%
C
er
ta
in
ty
 o
f e
vi
de
nc
e
What is 
the overall 
certainty of the 
evidence of 
effects?
  Very low
  Low
  Moderate
  High
  No included 
studies
The quality of the evidence for diagnostic accuracy 
ranks as very low and low. There is even less certainty 
about how diagnostic accuracy translates into effects 
on clinical outcomes.
No evidence on direct 
harms of procedures though 
probably low (most based 
on simple blood testing). 
Other harms related to 
diagnostic accuracy (see 
above); with low sensitivity/
high false-negative results 
for PB
Va
lu
es
Is there 
important 
uncertainty 
about, or 
variability in, 
the extent to 
which people 
value the main 
outcomes?
  Important 
uncertainty 
or variability
  Possibly 
important 
uncertainty 
or 
variability
  Probably no 
important 
uncertainty 
or variability
  No 
important 
uncertainty 
or variability
  No known 
undesirable 
outcomes
The main outcome is diagnosis by a laboratory test (no 
smear, no biopsy). People are likely to value diagnostic 
accuracy as an outcome but there is uncertainty about 
how diagnostic accuracy translates to clinical outcomes.
Providers would need 
to interpret a test that 
might be of a suboptimal 
accuracy (most likely for 
PB).
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Ba
la
nc
e 
of
 e
ff
ec
ts
Does the 
balance 
between 
desirable and 
undesirable 
effects 
favour the 
intervention 
or the 
comparison?
  Favours the 
comparison
  Probably 
favours the 
comparison
  Does not 
favour 
either the 
intervention 
or the 
comparison
  Probably 
favours the 
intervention
  Favours the 
intervention
  Varies
  Don't know
Low quality evidence on diagnostic accuracy, 
suboptimal sensitivity (particularly for PB leprosy), 
and unclear how diagnostic accuracy impacts clinical 
outcomes.
Re
so
ur
ce
s 
re
qu
ir
ed
How large are 
the resource 
requirements 
(costs)?
  Large costs
  Moderate 
costs
  Negligible 
costs and 
savings
  Moderate 
savings
  Large 
savings
  Varies
  Don't know
No research evidence was identified. The cost of the test likely 
to  vary  according to 
country and might require 
laboratory investments 
(equipment,  t raining , 
biosafety tools).
Cost–effectiveness difficult 
to calculate given the lack 
of data on impact on 
clinical outcomes.
Guidelines for the diagnosis, treatment and prevention of leprosy44
Judgement Research evidence Additional consideration
C
er
ta
in
ty
 o
f e
vi
de
nc
e 
of
 r
eq
ui
re
d 
re
so
ur
ce
s
What is the 
certainty of 
the evidence 
of resource 
requirements 
(costs)?
  Very low
  Low
  Moderate
  High
  No 
included 
studies
No research evidence was identified. See above regard ing 
variability in costs and 
resources.
C
os
t-
ef
fe
ct
iv
en
es
s
Does the cost–
effectiveness 
of the 
intervention 
favour the 
intervention 
or the 
comparison?
  Favours the 
comparison
  Probably 
favours the 
comparison
  Does not 
favour 
either the 
intervention 
or the 
comparison
  Probably 
favours the 
intervention
  Favours the 
intervention
  Varies
  No 
included 
studies
No research evidence was identified. It is difficult to estimate 
cost–effectiveness due to 
uncertainty regarding costs 
as well as effects on clinical 
outcomes.
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Eq
ui
ty
What would be 
the impact on 
health equity?
  Reduced
  Probably 
reduced
  Probably no 
impact
  Probably 
increased
  Increased
  Varies
  Don't know
Utilizing blood tests to diagnose leprosy might increase 
identification and reduce health inequity, if the test is 
sufficiently accurate and available in clinical settings.
A test not very sensitive for 
early forms of leprosy might 
lead to under-detection 
and under-treatment.
Concerns are expressed 
for increased cost for 
detection compared to 
clinical examination.
Ac
ce
pt
ab
ili
ty
Is the 
intervention 
acceptable 
to key 
stakeholders?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
No research evidence was identified, but stakeholders 
likely to vary with regard to acceptable diagnostic 
accuracy thresholds.
Stakeholders  may be 
reluctant to implement a 
laboratory test that is more 
expensive than clinical 
examination or other tests 
such as smear.
Patients might prefer to 
undergo a blood test than a 
more invasive confirmatory 
test such as smear or 
biopsy.
Fe
as
ib
ili
ty
Is the 
intervention 
feasible to 
implement?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
No research evidence was identified. Likely to vary 
depending on availability of testing resources.
The feasibility might be 
high only for referral 
centres.
Drawing blood might be 
simpler than performing a 
slit-skin smear or a biopsy.
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Summary of judgements
Judgement Implications
Problem No Probably no Probably yes Yes Varies Don't know
Desirable 
effects
Trivial Small Moderate Large Varies Don't know
Undesirable 
effects
Large Moderate Small Trivial Varies Don't know
Certainty of 
evidence
Very low Low Moderate High No included 
studies
Values Important 
uncertainty 
or variability
Possibly 
important 
uncertainty 
or variability
Probably no 
important 
uncertainty 
or variability
No 
important 
uncertainty 
or 
variability
No known 
undesirable 
outcomes
Balance of 
effects
Favours the 
comparison
Probably 
favours the 
comparison
Does not 
favour either 
intervention 
or 
comparison
Probably 
favours the 
intervention
Favours the 
intervention
Varies Don't know
Resources 
required
Large costs Moderate 
costs
Negligible 
costs and 
savings
Moderate 
savings
Large 
savings
Varies Don't know
Certainty 
of evidence 
of required 
resources
Very low Low Moderate High No included 
studies
Cost–
effectiveness
Favours the 
comparison
Probably 
favours the 
comparison
Does not 
favour either 
intervention 
or 
comparison
Probably 
favours the 
intervention
Favours the 
intervention Varies
No included 
studies
Equity Reduced Probably 
reduced
Probably no 
impact
Probably 
increased
Increased Varies Don't know
Acceptability No Probably no Probably yes Yes Varies Don't know
Feasibility No Probably no Probably yes Yes Varies Don't know
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Conclusion: Is there a diagnostic test for leprosy disease (PB and/or MB) that has 
sufficient sensitivity and specificity and whose use is feasible under programmatic 
conditions?
Type of 
recommendation
Strong 
recommendation 
against the 
intervention
Conditional 
recommendation 
against the 
intervention
Conditional 
recommendation 
for either the 
intervention or 
the comparison
Conditional 
recommendation 
for the 
intervention
Strong 
recommendation 
for the 
intervention
Recommendation The GDG does not recommend the addition of any biological test to current methods for the diagnosis of leprosy 
under programmatic conditions
Justification Although many studies have been published on additional biological tests for leprosy, almost all of them show insufficient 
accuracy for diagnosis, or they are not commercially/clinically available or feasible for use at the field level. Based on 
currently available evidence, they do not represent a clear advantage in comparison to clinical diagnosis or to current 
confirmatory tests such as slit-skin smear or skin biopsy.
The difficulty of interpreting a positive test among household contacts should be noted; specifically, it is difficult to 
determine whether a positive test is a false-positive or indication of preclinical infection.
The GDG acknowledges that the costs of such tests have not been reviewed.
Subgroup 
considerations
None.
Implementation 
considerations
There are no new implementation considerations as the current approach is based on current practice.
Monitoring and 
evaluation
There are no new monitoring or evaluation concerns.
Research priorities Assays that show promise of greater diagnostic accuracy and are feasible for use at the field level, should be tested in 
larger, well-designed studies that would allow assessment of their accuracy for detection among contacts.
Question 1b: Is there a diagnostic test for the detection of M. leprae infection 
(latent leprosy) among contacts that has sufficient sensitivity and specificity 
and whose use is feasible under programmatic conditions?
Population: Contacts of leprosy patients Background:
Under the operational plan of the Global 
Leprosy Strategy contacts (household 
contacts or social contacts depending on 
the epidemiological setting) are supposed 
to be screened for leprosy shortly after 
the detection and commencement of 
treatment of the “index” case and then 
screened annually for 5 years. Preventive 
treatment with SDR shows some efficacy. 
No major adverse events have been 
reported till date.
Intervention: ELISA tests
Antibodies to PGL-1, MMP-I and -II, NDO-LID
Immunochromatographic/lateral flow tests
PCR
Others
Comparison: No possibility to detect leprosy infection
Main outcomes: Sensitivity/specificity
Setting: All settings (low- and high-burden)
Perspective: Clinic/field
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Assessment
Judgement Research evidence Additional consideration
Pr
ob
le
m
Is the problem a 
priority?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
The treatment of all contacts with 
an effective, inexpensive and safe 
preventive tool might be an effective 
public health intervention limiting the 
usefulness of having a test to detect who 
among the exposed is infected. However, 
availability of a test for infection would 
help target a more specific and effective 
preventive intervention. The utility of a 
diagnostic test will be higher in settings 
in which high priority is placed on not 
treating uninfected exposed persons.
Considering the strong interest in 
using preventive tools for leprosy, the 
identification of persons with latent 
infection might be important to target 
preventive actions. It might also facilitate 
early detection among persons with 
known latent infection. It might be key 
to bring the burden to zero in very low 
endemic contexts.
On the other hand, feasibility of post-
exposure prophylaxis might limit the 
usefulness of a test for detection of 
infection (see research evidence).
D
es
ir
ab
le
 e
ff
ec
ts
How substantial 
are the desirable 
anticipated 
effects?
  Trivial
  Small
  Moderate
  Large
  Varies
  Don't know
Desirable anticipated effects:
Diagnosis might faci l i tate better 
targeting of preventive interventions, 
but low sensitivity and PPV together with 
unknown effects on outcomes associated 
with earlier detection result in unclear 
benefits.
The GDG considered that the tests are 
insufficiently accurate to allow detection 
of leprosy infection.
U
nd
es
ir
ab
le
 e
ff
ec
ts
How substantial 
are the 
undesirable 
anticipated 
effects?
  Large
  Moderate
  Small
  Trivial
  Varies
  Don't know
Undesirable anticipated effects:
Relatively few people with positive tests 
will go on to develop clinical leprosy 
(PPV 4%), thus many people would still 
be treated unnecessarily.
Stigmatization of infected persons 
perceived as having a disease.
Summary of findings:
Based on a systematic review of seven 
studies with at least 1-year follow-up on 
predictive utility of ELISA for anti-PGL-I 
for subsequent leprosy in contacts. 
Findings were similar when restricted 
to studies with longer (at least 4 years) 
follow-up. The quality of evidence was 
graded as low; it was downgraded two 
levels due to moderate risk of bias and 
serious inconsistency.
Condition 
(accuracy 
measure)
Estimate
Sens: Median 26% (2–39)
Spec: Median 89% (83–98)
PPV: Median 4% (1–18)
No evidence on direct harms of 
procedures though probably low (most 
based on simple blood testing). Other 
harms related to diagnostic accuracy (see 
above); with low sensitivity/high false-
negative results/low predictive values
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C
er
ta
in
ty
 o
f e
vi
de
nc
e
What is the 
overall certainty 
of the evidence of 
effects?
  Very low
  Low
  Moderate
  High
  No included 
studies
The quality of the evidence for tests 
to detect infection ranks as moderate; 
however, the number of studies is 
limited.
No evidence of impact on clinical 
outcome.
Va
lu
es
Is there important 
uncertainty about, 
or variability 
in, the extent to 
which people 
value the main 
outcomes?
  Important 
uncertainty or 
variability
  Possibly 
important 
uncertainty or 
variability
  Probably no 
important 
uncertainty or 
variability
  No important 
uncertainty or 
variability
  No known 
undesirable 
outcomes
People are likely to value the main 
outcome (diagnostic accuracy for 
predicting subsequent clinical leprosy); 
however, there is uncertainty regarding 
how diagnostic accuracy translates to 
clinical outcomes.
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Ba
la
nc
e 
of
 e
ff
ec
ts
Does the balance 
between desirable 
and undesirable 
effects favour the 
intervention or 
the comparison?
  Favours the 
comparison
  Probably 
favours the 
comparison
  Does not favour 
either the 
intervention or 
the comparison
  Probably 
favours the 
intervention
  Favours the 
intervention
  Varies
  Don't know
Low quality evidence on predictive 
utility; don’t know how predictive utility 
translates to clinical outcomes.
Re
so
ur
ce
s 
re
qu
ir
ed
How large are 
the resource 
requirements 
(costs)?
  Large costs
  Moderate costs
  Negligible costs 
and savings
  Moderate 
savings
  Large savings
  Varies
  Don't know
No research evidence was identified. 
Resource requirements will depend on 
the costs of the assays (plus associated 
facility/personnel costs).
No evidence on costs of post-exposure 
prophylaxis versus testing and periodical 
screening.
C
er
ta
in
ty
 o
f e
vi
de
nc
e 
of
 r
eq
ui
re
d 
re
so
ur
ce
s
What is the 
certainty of 
the evidence 
of resource 
requirements 
(costs)?
  Very low
  Low
  Moderate
  High
  No included 
studies
No research evidence was identified. 
Costs of the assays are likely to vary 
across settings.
Need to compare costs of post-exposure 
prophylaxis against costs of testing paired 
with post-exposure prophylaxis and/or 
close clinical follow up/screening.
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C
os
t-
ef
fe
ct
iv
en
es
s
Does the cost–
effectiveness of 
the intervention 
favour the 
intervention or 
the comparison?
  Favours the 
comparison
  Probably 
favours the 
comparison
  Does not favour 
either the 
intervention or 
the comparison
  Probably 
favours the 
intervention
  Favours the 
intervention
  Varies
  No included 
studies
No research evidence was identified. No cost–effectiveness analysis is possible 
since there are no data on impact on 
outcomes. Must consider cost of testing 
household contacts versus prophylactic 
treatment without testing.
Eq
ui
ty
What would be 
the impact on 
health equity?
  Reduced
  Probably 
reduced
  Probably no 
impact
  Probably 
increased
  Increased
  Varies
  Don't know
Concern about stigma in persons who 
test positive but do not develop clinical 
leprosy.
A test that is not very sensitive might 
lead to under-use of potentially effective 
preventive tools.
Ac
ce
pt
ab
ili
ty
Is the intervention 
acceptable to key 
stakeholders?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
No research evidence was identified. 
Acceptability likely to depend on how 
stakeholders view use of prophylactic 
treatments in contacts and low sensitivity 
of the assay.
Stakeholders may be reluctant to 
implement a laboratory test that lacks 
sensitivity/PPV.
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Fe
as
ib
ili
ty
Is the intervention 
feasible to 
implement?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
No research evidence was identified. 
Feasibility will vary depending on the 
cost/availability of the assays.
The feasibility might be there only for 
referral centres.
Summary of judgements
Judgement Implications
Problem No Probably no Probably yes Yes Varies Don't know
Desirable 
effects
Trivial Small Moderate Large Varies Don't 
know
Undesirable 
effects
Large Moderate Small Trivial Varies Don't 
know
Certainty of 
evidence
Very low Low Moderate High No 
included 
studies
Values Important 
uncertainty 
or variability
Possibly 
important 
uncertainty 
or variability
Probably no 
important 
uncertainty 
or variability
No 
important 
uncertainty 
or variability
No known 
undesirable 
outcomes
Balance of 
effects
Favours the 
comparison
Probably 
favours the 
comparison
Does not 
favour 
either the 
intervention 
or the 
comparison
Probably 
favours the 
intervention
Favours the 
intervention
Varies Don't 
know
Resources 
required
Large costs Moderate 
costs
Negligible 
costs and 
savings
Moderate 
savings
Large savings Varies Don't 
know
Certainty 
of evidence 
of required 
resources
Very low Low Moderate High No 
included 
studies
Cost–
effectiveness
Favours the 
comparison
Probably 
favours the 
comparison
Does not 
favour 
either the 
intervention 
or the 
comparison
Probably 
favours the 
intervention
Favours the 
intervention Varies
No 
included 
studies
Equity Reduced Probably 
reduced
Probably no 
impact
Probably 
increased
Increased Varies Don't know
Acceptability No Probably no Probably yes Yes Varies Don't 
know
Feasibility No Probably no Probably yes Yes Varies Don't know
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Conclusion: Is there a diagnostic test for the detection of M. leprae infection (latent 
leprosy) among contacts that has sufficient sensitivity and specificity and whose use is 
feasible under programmatic conditions?
Type of 
recommendation
Strong 
recommendation 
against the 
intervention
Conditional 
recommendation 
against the 
intervention
Conditional 
recommendation 
for either the 
intervention or 
the comparison
Conditional 
recommendation 
for the 
intervention
Strong 
recommendation 
for the 
intervention
Recommendation The GDG does not recommend a test to identify contacts at higher risk for developing subsequent 
leprosy disease.
Justification Low accuracy shown by the tests studied. The GDG recognizes that the costs of such tests have not 
been reviewed.
Subgroup 
considerations
None.
Implementation 
considerations
There are no implementation considerations as the current approach does not include testing 
household contacts for infection.
Monitoring and 
evaluation
There are no new monitoring or evaluation concerns.
Research priorities Further studies are needed to identify new accurate biomarkers of leprosy infection to be used to 
develop a test for detecting infection under field conditions.
Question 2a: Is a single (uniform) treatment regimen for all patients with 
leprosy as effective and safe as the two currently recommended treatment 
regimens: the one for MB leprosy with a combination of three drugs for 12 
months and the one for PB leprosy with a combination of two drugs for 6 
months?
Population: Adults and children with PB 
and MB leprosy
Background:
Presently, there are two regimens for treating 
leprosy based on disease classification into 
PB and MB leprosy. However, some patients 
might be wrongly classified (usually MB leprosy 
misclassified as PB leprosy). Shorter treatment 
regimens are likely to be more acceptable and 
less costly. Epidemiological evidence exists of a 
higher relapse rate after treatment in PB patients 
using a shorter 2-drug regimen compared to 
treatment in MB patients using a longer 3-drug 
regimen. Moreover, there is evidence of some 
degree of misclassification of PB based on lesion 
counts when compared to skin smear findings.
Intervention: Uniform regimen with three 
drugs
Comparison: PB regimen: two drugs for 6 
months
MB regimen: three drugs for 
12 months
Main 
outcomes:
Clinical improvement
Reactions
Relapse
Adverse events
Setting: Clinical and field setting
Perspective: Clinician
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Assessment
Judgement Research evidence Additional 
consideration
Pr
ob
le
m
Is the 
problem a 
priority?
  No
  Probably 
no
  Probably 
yes
  Yes
  Varies
  Don't know
Leprosy is a condition with important clinical, 
social and public health consequences. Effective 
treatments are an important priority. At a public 
health level having a single regimen effective for 
all types of leprosy would be desirable given 
limited availability of expertise in classification 
of leprosy. A single regimen may also facilitate 
the logistics of drug distribution.
With the management 
of leprosy at the primary 
health-care level, having 
a single regimen might 
be beneficial.
The risk of receiving a 
suboptimal treatment 
regimen for wrongly 
classified PB cases might 
be reduced.
D
es
ir
ab
le
 e
ff
ec
ts
How 
substantial 
are the 
desirable 
anticipated 
effects?
  Trivial
  Small
  Moderate
  Large
  Varies
  Don't know
Desirable anticipated effects:
A 3-drug 6-month regimen may be beneficial in 
PB patients by improving clinical and histological 
outcomes compared with a 2-drug 6-month 
regimen
In MB patients, one RCTfound a 3-drug 6-month 
regimen associated with non-statistically 
significant trend towards increased risk of 
relapse versus a 3-drug 12-month regimen, 
but the estimate was very imprecise. One non-
randomized study found a 3-drug 6-month 
regimen associated with a trend towards worse 
clinical outcomes at 6 months than a 12-month 
regimen.
The GDG considered that 
the risk of misclassification 
of patients in the field 
might be an issue and 
that, together with the 
evidence of the benefits 
of a 3-drug regimen for PB 
leprosy could justify the 
recommendation of using 
a 3-drug regimen for both 
forms of the disease. For 
PB leprosy, some evidence 
of superior outcomes with 
a 3-drug 6-month regimen 
versus a 2-drug 6-month 
regimen. For MB leprosy, 
the available evidence 
does not provide enough 
certainty on potential 
r isks associated with 
a shorter regimen, i.e. 
worse clinical outcomes 
and risk for relapse. The 
results on side-effects 
and compliance seem to 
be encouraging, though 
again very limited. The 
GDG concluded that 
using a 3-drug PB regimen 
for 6 months might be 
associated with improved 
clinical outcomes while 
there was insufficient 
evidence to shorten 
the duration of 3-drug 
therapy for MB patients 
from 12 to 6 months.
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consideration
U
nd
es
ir
ab
le
 e
ff
ec
ts
How 
substantial 
are the 
undesirable 
anticipated 
effects?
  Large
  Moderate
  Small
  Trivial
  Varies
  Don’t know
Undesirable anticipated effects:
UMDT (3-drug 6-month regimen) may be 
associated with adverse events and/or lower 
compliance in PB patients
Summary of findings:
UMDT (3-drug 6-month regimen) vs MB-MDT 
and PB-MDT
Outcome Effect estimate Quality
PB
Good clinical 
outcome at 6 
months
RR 1.9 (0.4–8.6) 
and 3.3 (1.7–6.7)
Very low
12 months RR 2.0 (0.4–8.6) 
and 1.1 (1.0–1.3)
Very low
24 months RR 1.4 (0.8–2.7) Very low
Good histological 
outcome at 6 
months
RR 1.1 (0.7–1.8) 
and 1.6 (1.2–2.2)
Very low
12 months RR 1.2 
(0.9–1.6) and 1
Very low
MB
Good clinical 
outcome at 12 
months
RR 0.12 (0.01–
1.9)
Very low
24 months 0.33 (0.06–1.8) Very low
Good histological 
outcome at 12 
months
0.5 (0.12–1.8) Very low
Relapses RCT: RR 6.2 
(0.78–61)
Non-RCT: no 
relapses in 
>1600 patients
Very low
Death 7.6% vs 8.6%
P = 0.48
Low
Adverse event Effect estimate SOE
Leprosy reactions 
in PB
  RR 1.5 
(0.7z7–3.0 
and 2.4 
(0.11–56)
Low
Leprosy reactions 
in MB 
RR 1.0 (0.86–
1.30)
Low
Anaemia in PB RR 13.0 (0.78–
216)
Very low
Several uncontrolled 
studies included in the 
evidence review, not 
included in the table.
For  the  PB  g roup , 
there is at least some 
trend towards better 
clinical and histological 
outcomes. But in the 
MB group data were 
somewhat mixed: no 
difference in risk of 
death, no difference in 
risk of disability; possibly 
higher risk of relapse in 
the UMDT arm of the 
only RCT.
For PB leprosy, 10 to 14 
more patients for 100 
treated with a 3-drug 
regimen estimated to 
have a good clinical 
o u t c o m e  a f t e r  1 2 
m o n t h s ,  2 6  m o r e 
patients for 100 treated 
with a 3-drug regimen 
estimated to have a 
good outcome after 24 
months, compared with 
treatment with a 2-drug 
regimen.
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Judgement Research evidence Additional 
consideration
C
er
ta
in
ty
 o
f e
vi
de
nc
e
What is 
the overall 
certainty of 
the evidence 
of effects?
  Very low
  Low
  Moderate
  High
  No 
included 
studies
Data on effects of UMDT vs MB-MDT in patients 
with MB leprosy are from one RCT, otherwise 
quasi-randomized or non-randomized studies. 
Data on risk of relapse in patients with MB 
leprosy are scarce (an imprecise estimate 
from one RCT and no cases in a large non-
randomized study).
Va
lu
es
Is there 
important 
uncertainty 
about, or 
variability in, 
the extent 
to which 
people value 
the main 
outcomes?
  Important 
uncertainty 
or 
variability
  Possibly 
important 
uncertainty 
or 
variability
  Probably 
no 
important 
uncertainty 
or 
variability
  No 
important 
uncertainty 
or 
variability
  No known 
undesirable 
outcomes
Main outcome is clinical improvement/cure, 
which is likely to be highly valued by most 
persons.
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Judgement Research evidence Additional 
consideration
Ba
la
nc
e 
of
 e
ff
ec
ts
Does the 
balance 
between 
desirable and 
undesirable 
effects 
favour the 
intervention 
or the 
comparison?
  Favours the 
comparison
  Probably 
favours the 
comparison
  Does not 
favour 
either the 
intervention 
or the 
comparison
  Probably 
favours the 
intervention
  Favours the 
intervention
  Varies
  Don't know
In PB patients, the benefit of a 3-drug treatment 
in clinical outcomes appears to outweigh harms.
In MB patients, it is less clear if benefits of a 
3-drug 6-month regimen on clinical outcomes 
outweigh harms due to the potential for worse 
short-term clinical outcomes and relapse, based 
on limited evidence.
Different comparisons 
a n d  f i n d i n g s  f o r 
treatment of PB and 
MB leprosy.
Re
so
ur
ce
s 
re
qu
ir
ed
How large are 
the resource 
requirements 
(costs)?
  Large costs
  Moderate 
costs
  Negligible 
costs and 
savings
  Moderate 
savings
  Large 
savings
  Varies
  Don't know
No research evidence was identified. The cost 
of a 3-drug regimen is higher in PB patients and 
the cost of a 6-month regimen is lower in MB 
patients than current regimens; costs may be 
lowered by the simplified logistics of the same 
3-drug combination for all leprosy patients on 
the part of pharmaceutical company providing 
the drugs. If a 6-month regimen was to be used 
for MB patients, there would be additional costs 
related to the need for follow-up in MB patients 
to monitor for relapse.
MDT is provided free 
of charge to patients 
based on an agreement 
with a pharmaceutical 
company. Probably the 
costs of producing a 
3-drug combination 
o n l y  w i l l  n o t  b e 
substant ia l ly  higher 
than producing two 
different combinations 
of medications.
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Judgement Research evidence Additional 
consideration
C
er
ta
in
ty
 o
f e
vi
de
nc
e 
of
 r
eq
ui
re
d 
re
so
ur
ce
s
What is the 
certainty of 
the evidence 
of resource 
requirements 
(costs)?
  Very low
  Low
  Moderate
  High
  No 
included 
studies
No research evidence was identified. See above. If the pharmaceutical 
company increases the 
availability of MB-MDT 
(3-drug combination), 
there might be no costs 
for programmes
C
os
t–
ef
fe
ct
iv
en
es
s
Does the 
cost–
effectiveness 
of the 
intervention 
favour the 
intervention 
or the 
comparison?
  Favours the 
comparison
  Probably 
favours the 
comparison
  Does not 
favour 
either the 
intervention 
or the 
comparison
  Probably 
favours the 
intervention
  Favours the 
intervention
  Varies
  No 
included 
studies
No research evidence was identified. Difficult to 
estimate cost–effectiveness due to uncertainty 
regarding clinical outcomes.
Hard to estimate cost–
effectiveness given the 
limited clinical outcome 
data and differential 
effects in various groups; 
also costs of follow-up 
examinations have to be 
accounted for.
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Judgement Research evidence Additional 
consideration
Eq
ui
ty
What would 
be the impact 
on health 
equity?
  Reduced
  Probably 
reduced
  Probably 
no impact
  Probably 
increased
  Increased
  Varies
  Don't know
UMDT may increase health equity by providing 
a uniform regimen that is not dependent on 
expertise in classification of leprosy, in settings 
where leprosy expertise is limited or not 
available.
The reduced length of 
MB treatment is likely 
to facilitate compliance 
and reduce the need of 
visits to the health facility. 
The protective factor in 
PB leprosy might reduce 
costs associated with 
relapses and reactions.
Patients referred to 
primary health-care 
centres where fewer skills 
are available compared 
to referral centres for 
disease classification, 
they will all receive a 
single regimen.
Ac
ce
pt
ab
ili
ty
Is the 
intervention 
acceptable 
to key 
stakeholders?
  No
  Probably 
no
  Probably 
yes
  Yes
  Varies
  Don't know
No research evidence was identi f ied. 
Acceptability may be influenced by preferences 
regarding the use of traditional regimens for PB 
and MB leprosy.
Stakeholders may be 
reluctant to implement 
a  sho r t e r  r e g imen 
since leprosy has been 
treated for years in 
the past and since it is 
difficult to assess clinical 
improvement because 
lesions do not disappear 
quickly.
Patients might prefer to 
take a shorter-duration 
treatment.
Fe
as
ib
ili
ty
Is the 
intervention 
feasible to 
implement?
  No
  Probably 
no
  Probably 
yes
  Yes
  Varies
  Don't know
No research evidence was identi f ied. 
Implementation may be easier because UMDT 
does not require that leprosy be accurately 
classified. Patients with MB leprosy may require 
additional follow-up to ensure adequate 
treatment response.
Ea s i e r  ca re  a t  the 
primary health-care level 
with reduced costs for 
both the health system 
and patients. Limited 
capacity to differentiate 
between PB and MB 
leprosy at the primary 
health-care level might 
be overcome by a single 
regimen.
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Summary of judgements
Judgement Implications
Problem No Probably no Probably yes Yes Varies Don't know
Desirable 
effects
Trivial Small Moderate Large Varies Don't know
Undesirable 
effects
Large Moderate Small Trivial Varies Don't know
Certainty of 
evidence
Very low Low Moderate High No included 
studies
Values Important 
uncertainty 
or variability
Possibly 
important 
uncertainty or 
variability
Probably no 
important 
uncertainty 
or 
variability
No 
important 
uncertainty 
or variability
No known 
undesirable 
outcomes
Balance of 
effects
Favours the 
comparison
Probably 
favours the 
comparison
Does not 
favour either 
intervention 
or 
comparison
Probably 
favours the 
intervention
Favours the 
intervention
Varies Don't know
Resources 
required
Large costs Moderate 
costs
Negligible 
costs and 
savings
Moderate 
savings
Large savings Varies Don't know
Certainty 
of evidence 
of required 
resources
Very low Low Moderate High No included 
studies
Cost–
effectiveness
Favours the 
comparison
Probably 
favours the 
comparison
Does not 
favour either 
intervention 
or 
comparison
Probably 
favours the 
intervention
Favours the 
intervention Varies
No included 
studies
Equity Reduced Probably 
reduced
Probably no 
impact
Probably 
increased
Increased Varies Don't know
Acceptability No Probably no Probably yes Yes Varies Don't know
Feasibility No Probably no Probably 
yes
Yes Varies Don't know
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Conclusion: Is a single (uniform) treatment regimen for all patients with leprosy as 
effective and safe as the two currently recommended treatment regimens: the one 
for MB leprosy with a combination of three drugs for 12 months and the one for PB 
leprosy with a combination of two drugs for 6 months?
Type of 
recommendation
Strong 
recommendation 
against the 
intervention
Conditional 
recommendation 
against the 
intervention
Conditional 
recommendation 
for either the 
intervention or 
the comparison
Conditional 
recommendation 
for the 
intervention
Strong 
recommendation 
for the 
intervention
Recommendation The GDG recommends the use of a 3-drug regimen with rifampicin, dapsone and 
clofazimine for all patients with leprosy with a duration of treatment of 6 months for PB 
leprosy and of 12 months for MB leprosy.
Justification For PB there is some evidence of better outcomes with three drugs; for every 100 patients 
treated with three drugs instead of two, there would be an estimated 10 to 14 more 
patients with good clinical outcomes at 1 year and 26 more patients with good clinical 
outcomes at 2 years. There is not enough evidence of equivalent outcomes to shorten 
the duration of treatment of MB from 12 to 6 months. The uniform regimen in terms of 
number of drugs may partially mitigate the adverse consequences of misclassification of 
MB leprosy as PB leprosy.
Subgroup 
considerations
Duration of treatment is different for PB and MB leprosy.
Implementation 
considerations
The cost of treatment for PB leprosy is increased with three drugs but the reduced drug 
management cost might help offset the costs. Having a uniform combination of drugs may 
make it easier to implement in the field and reduce the effect of potential misclassification. 
However, training of health-care workers would still be needed. It would be advisable to 
develop standard health education material to further support adherence to the new 
treatment recommendations by both health-care workers and patients.
Monitoring and 
evaluation
Monitoring of compliance among PB patients after change of regimen from two to three 
drugs.
Monitoring of adverse events through pharmacovigilance would be needed.
Research 
priorities
Studies on tools for bacteriological tests (including on M. leprae bacilli viability) to 
effectively monitor the outcomes among patients are needed along with studies on tools 
to differentiate relapse from persistence of lesion activity, reactions and reinfections. 
Studies on neuritis, its immunological aspects and on clinical management of reactions 
are needed to reduce the disability progression and/or occurrence during and after 
antibiotic treatment.
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Question 2b: Which treatment regimen has better efficacy and safety for 
leprosy patients detected with resistance to rifampicin, with or without 
associated resistance to dapsone or ofloxacin?
Population: Adults and children with 
detected resistance to 
rifampicin
Background:
There is increasing evidence of the existence 
of resistance to drugs in leprosy and WHO is 
launching a new surveillance guide that aims to 
expand the availability of data and widen access 
to detection of resistance for individual patients. 
In 2010, the Expert Committee formulated 
recommendations for treatment using second-
line drugs on the basis of expert opinion, but 
no leprosy guidelines were ever formulated; 
the suggestions for treatment of such patients 
have never been stated as part of a guideline 
document.
Intervention: Second-line treatment 
regimens
Comparison: MB-MDT
Main outcomes: Clinical and histological 
outcomes
Setting: Clinical and field setting
Perspective: Clinician/health system
Assessment
Judgement Research evidence Additional consideration
Pr
ob
le
m
Is the problem a 
priority?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
The magnitude of patient testing 
for resistance globally (small) does 
not allow for accurate assessment 
of the extent of the problem of 
drug resistance. However, all 
the high-burden countries have 
reported resistance among new 
and previously treated cases.
No evidence on how detected 
resistance impacts cl inical 
outcomes.
Five studies reported prevalence 
of rifampicin resistance: 1.36% 
in new cases, 8% in relapsed 
cases.
Formal reports were received 
concerning a total of 1086 
relapsed cases and of 776 new 
cases tested globally before the 
end of 2015, among which 
resistance to rifampicin was 
identified in 57 cases (5.2%) and 
16 cases (2.1%), respectively 
(unpublished data from the 
latest coordination meeting of 
the surveillance network 2016).
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Judgement Research evidence Additional consideration
D
es
ir
ab
le
 e
ff
ec
ts
How substantial 
are the desirable 
anticipated effects?
  Trivial
  Small
  Moderate
  Large
  Varies
  Don't know
Desirable anticipated effects:
Unable to estimate due to lack 
of evidence.
The GDG considered that in 
view of the lack of evidence 
there was still a need to provide 
recommendations on second-
line treatment for cases found 
with resistance. For patients who 
started MDT and obtained the 
drug resistance testing results 
during the course of treatment, 
the GDG experts’ opinion 
is to ignore the duration of 
treatment already taken in case 
of resistance to rifampicin and to 
start a full course of second-line 
treatment, independently of the 
clinical outcomes under MDT.
U
nd
es
ir
ab
le
 e
ff
ec
ts
How substantial 
are the undesirable 
anticipated effects?
  Large
  Moderate
  Small
  Trivial
  Varies
  Don’t know
Unable to estimate due to lack 
of evidence
Summary of findings:
No studies on second-line 
treatment for patients with drug 
resistance.
The GDG considered that in 
view of the lack of evidence 
there was still a need to provide 
recommendations on second-
line treatment for cases found 
with drug resistance. For patients 
who start MDT and obtain 
drug resistance testing results 
during the course of treatment, 
the GDG experts’ opinion 
is to ignore the duration of 
treatment already taken in case 
of resistance to rifampicin and 
to start a full course of second-
line treatment, independent of 
clinical outcomes with MDT.
C
er
ta
in
ty
 o
f e
vi
de
nc
e
What is the overall 
certainty of the 
evidence of effects?
  Very low
  Low
  Moderate
  High
  No included 
studies
No data.
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Judgement Research evidence Additional consideration
Va
lu
es
Is there important 
uncertainty about, 
or variability in, 
the extent to which 
people value the 
main outcomes?
  Important 
uncertainty or 
variability
  Possibly 
important 
uncertainty or 
variability
  Probably no 
important 
uncertainty or 
variability
  No important 
uncertainty or 
variability
  No known 
undesirable 
outcomes
The main outcome is successful 
treatment of patients with 
detected resistance; likely to be 
highly valued by people.
Ba
la
nc
e 
of
 e
ff
ec
ts
Does the balance 
between desirable 
and undesirable 
effects favour the 
intervention or the 
comparison?
  Favours the 
comparison
  Probably favours 
the comparison
  Does not favour 
either the 
intervention or 
the comparison
  Probably favours 
the intervention
  Favours the 
intervention
  Varies
  Don't know
No research evidence was 
identified.
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Judgement Research evidence Additional consideration
Re
so
ur
ce
s 
re
qu
ir
ed
How large are 
the resource 
requirements 
(costs)?
  Large costs
  Moderate costs
  Negligible costs 
and savings
  Moderate savings
  Large savings
  Varies
  Don't know
No research evidence was 
identified.
C
er
ta
in
ty
 o
f e
vi
de
nc
e 
of
 r
eq
ui
re
d 
re
so
ur
ce
s
What is the 
certainty of 
the evidence 
of resource 
requirements 
(costs)?
  Very low
  Low
  Moderate
  High
  No included 
studies
No research evidence was 
identified.
C
os
t–
ef
fe
ct
iv
en
es
s
Does the cost–
effectiveness of the 
intervention favour 
the intervention or 
the comparison?
  Favours the 
comparison
  Probably favours 
the comparison
  Does not favour 
either the 
intervention or 
the comparison
  Probably favours 
the intervention
  Favours the 
intervention
  Varies
  No included 
studies
No research evidence was 
identified.
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Judgement Research evidence Additional consideration
Eq
ui
ty
What would be the 
impact on health 
equity?
  Reduced
  Probably 
reduced
  Probably no 
impact
  Probably 
increased
  Increased
  Varies
  Don't know
No research evidence was 
identified. Some patients may not 
be able to afford/access second-
line treatments.
MDT is free of charge but this 
may not necessarily apply to 
second-line drugs; therefore, 
some patients might not be able 
to access medications especially 
for 24 months
Ac
ce
pt
ab
ili
ty
Is the intervention 
acceptable to key 
stakeholders?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
No research evidence was 
identified. Costs may vary in 
different settings and impact 
acceptability.
Programmes might be reluctant 
to implement due to potential 
costs (limited in any case by 
the probable small number of 
cases).
Fe
as
ib
ili
ty
Is the intervention 
feasible to 
implement?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
No research evidence was 
identified. Alternative regimens 
are available but may be more 
cost ly  and require longer 
treatment.
May be feasible only for patients 
who can afford a longer-duration 
treatment.
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Summary of judgements
Judgement Implications
Problem No Probably no Probably yes Yes Varies Don't know
Desirable 
effects
Trivial Small Moderate Large Varies Don't know
Undesirable 
effects
Large Moderate Small Trivial Varies Don't know
Certainty of 
evidence
Very low Low Moderate High No included 
studies
Values Important 
uncertainty 
or variability
Possibly 
important 
uncertainty 
or variability
Probably no 
important 
uncertainty 
or variability
No important 
uncertainty or 
variability
No known 
undesirable 
outcomes
Balance of 
effects
Favours the 
comparison
Probably 
favours the 
comparison
Does not 
favour either 
intervention 
or 
comparison
Probably 
favours the 
intervention
Favours the 
intervention
Varies Don't know
Resources 
required
Large costs Moderate 
costs
Negligible 
costs and 
savings
Moderate 
savings
Large savings Varies Don't know
Certainty 
of evidence 
of required 
resources
Very low Low Moderate High No included 
studies
Cost–
effectiveness Favours the 
comparison
Probably 
favours the 
comparison
Does not 
favour either 
intervention 
or 
comparison
Probably 
favours the 
intervention
Favours the 
intervention Varies
No included 
studies
Equity Reduced Probably 
reduced
Probably no 
impact
Probably 
increased
Increased Varies Don't know
Acceptability No Probably no Probably yes Yes Varies Don't know
Feasibility No Probably no Probably yes Yes Varies Don't know
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Conclusion: Which treatment regimen has better efficacy and safety for leprosy 
patients detected with resistance to rifampicin alone and/or with associated resistance 
to dapsone and ofloxacin?
Type of 
recommendation
Strong 
recommendation 
against the 
intervention
Conditional 
recommendation 
against the 
intervention
Conditional 
recommendation 
for either the 
intervention or 
the comparison
Conditional 
recommendation 
for the 
intervention
Strong 
recommendation 
for the 
intervention
Recommendation The GDG recommends that patients detected with resistance to rifampicin use at least two second-
line drugs (clarithromycin, minocycline, ofloxacin/levofloxacin/moxifloxacin) plus clofazimine daily 
for 6 months, then clofazimine plus one of these drugs daily for an additional 18 months. In case of 
associated ofloxacin resistance, ofloxacin/levofloxacin/moxifloxacin should not be chosen.
Justification Patients with drug-resistant M. leprae would benefit from second-line treatment. Despite lack of 
evidence on effective regimens for drug-resistant M. leprae, several drugs are known to have an 
effect against M. leprae and can be incorporated into second-line treatments. Molecular testing of 
resistance may help guide selection of second-line regimens.
Subgroup 
considerations
None.
Implementation 
considerations
There are concerns regarding implementation as the current approach is not routinely implemented. 
Second-line regimens may be more costly and require longer duration of treatment.
Monitoring and 
evaluation
Data on resistance must be expanded and trends have to be monitored. Additional data on 
second-line treatment outcomes should be collected as per guidance included in the “A guide for 
surveillance of antimicrobial resistance in leprosy-2017 Update” (WHO Regional Office for South-
East Asia, October 2017). Pharmacovigilance to properly monitor adverse events shall be put in 
place.
Research 
priorities
The GDG emphasizes the need to enhance the current antimicrobial resistance surveillance 
for leprosy. Given the low burden of leprosy disease, it is unlikely that an RCT of the efficacy of 
different second-line regimens can be carried out. However, systematic collection of clinical and 
bacteriological outcomes for different regimens used for drug-resistant M. leprae using observational 
methods would be useful for understanding potential benefits and harms.
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Question 3a: Is there an effective and safe chemoprophylaxis regimen for 
prevention of leprosy among contacts of leprosy patients and for high-risk 
populations that could be used under programmatic conditions?
Population: Adults and children contacts 
of patients with PB and MB 
leprosy
Population of endemic areas
Background:
Contact screening has been recommended as 
a core programmatic intervention since 2010. 
However, despite the demonstrated higher risk 
of contacts for developing leprosy, to date no 
studies so far has clearly shown the efficacy of any 
post-exposure preventive regimen except with 
extended use of dapsone. Additionally, it is noted 
that contact screening, though recommended, 
has not been carried out effectively by most 
leprosy programmes.
Intervention: SDR post-exposure prophylaxis 
for contacts
Double-dose rifampicin 
post-exposure prophylaxis for 
contacts
Double-dose rifampicin 
post-exposure prophylaxis for 
population in endemic areas
Comparison: No intervention (no 
chemoprophylaxis)
Main 
outcomes:
Occurrence of leprosy disease
Adverse events
Setting: All settings
Perspective: Clinic/field
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Assessment
Judgement Research evidence Additional consideration
Pr
ob
le
m
Is the problem a 
priority?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
Leprosy is associated with 
important clinical and social 
c o n s e q u e n c e s .  A l t h o u g h 
effective antibiotic treatments are 
available, prevention of disease 
would be preferable and may 
have additional public health 
benefits for containing further 
spread of disease and reduction 
in disability.
With the possibility of prevention, 
the burden of leprosy is likely 
to be significantly reduced. 
Additionally, the availability of 
a preventive treatment, even 
if only partly effective, is likely 
to improve the screening of 
contacts, facilitating earlier 
detection of the disease.
D
es
ira
bl
e 
ef
fe
ct
s
How substantial 
are the desirable 
anticipated effects?
  Trivial
  Small
  Moderate
  Large
  Varies
  Don't know
Desirable anticipated effects:
SDR is associated with a reduction 
in risk of leprosy of ~30% over 
5–6 years versus placebo in 
contacts.
The number needed to treat 
to prevent one case of leprosy 
infection is ~333.
Although the implementation of 
the study was only in one country, 
preliminary reports from the 
multicountry feasibility study are 
encouraging. However, because 
leprosy is a highly stigmatized 
disease, caution must be 
taken when implementing 
SDR for contacts outside the 
family of the patient and the 
programmes must respect the 
wishes of patients to disclose or 
not disclose their diagnosis of 
leprosy. With no authorization 
to disclose, no screening of 
contacts should be carried out, 
nor should preventive treatment 
to contacts without leprosy 
disease be prescribed. The group 
concluded that in areas of high 
endemicity and overcrowding a 
“blanket” approach using SDR 
for the whole community could 
be considered, although there 
is only one study showing the 
efficacy of such an approach. 
The availability of a preventive 
treatment is likely to improve 
the quality and completeness 
of contact screening.   
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Judgement Research evidence Additional consideration
U
nd
es
ira
bl
e 
ef
fe
ct
s
How substantial 
are the undesirable 
anticipated effects?
  Large
  Moderate
  Small
  Trivial
  Varies
  Don't know
Undesirable anticipated effects:
No data on adverse events (likely 
to be limited since treatment 
is a single dose of rifampicin). 
Protection and benefits appear to 
occur only in the first 1–2 years. 
Summary of findings:
SDR vs placebo.
Outcome Effect estimate Quality*
Leprosy 
diagnosis 
1–2 years
0.3% vs 
0.7%
RR 0.43 
(0.28–0.67)
Moderate
Leprosy 
diagnosis 
3–4 years
0.6% vs 
0.9% 
RR 0.65 
(0.47–0.90)
Moderate
Leprosy 
diagnosis 
5–6 years
0.8% vs 
1.1%
RR 0.72 
(0.54–0.6
Moderate
*The quality of evidence was downgraded 
one level because inconsistency could not 
be assessed (estimates were based on 
one study).
No evidence on direct harms 
f rom procedures  though 
probably low (most based on 
simple blood testing). Other 
harms related to diagnostic 
accuracy (see above); with low 
sensitivity/high false-negative 
results/low predictive values.
For every 1000 contacts treated 
with SDR, four cases of leprosy 
are prevented after 1–2 years 
and three cases are prevented 
after 5–6 years.
C
er
ta
in
ty
 o
f e
vi
de
nc
e
What is the overall 
certainty of the 
evidence of effects?
  Very low
  Low
  Moderate
  High
  No included 
studies
Estimates of effects are based 
on a large, placebo-controlled, 
double-blind RCT with follow-up 
over 5–6 years
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Judgement Research evidence Additional consideration
Va
lu
es
Is there important 
uncertainty about, 
or variability in, the 
extent to which 
people value the 
main outcomes?
  Important 
uncertainty or 
variability
  Possibly important 
uncertainty or 
variability
  Probably no 
important 
uncertainty or 
variability
  No important 
uncertainty or 
variability
  No known 
undesirable 
outcomes
The main outcome, prevention of 
leprosy, is likely to be important 
to people. There may be some 
variability in interpretation of the 
magnitude of benefit or duration 
of benefits.
The only partial and temporary 
protection might be interpreted 
d i f f e r en t l y  b y  d i f f e r en t 
stakeholders.
Ba
la
nc
e 
of
 e
ffe
ct
s
Does the balance 
between desirable 
and undesirable 
effects favour the 
intervention or the 
comparison?
  Favours the 
comparison
  Probably favours 
the comparison
  Does not favour 
either the 
intervention or the 
comparison
  Probably favours 
the intervention
  Favours the 
intervention
  Varies
  Don't know
The results of the RCT suggest 
desirable effects on preventing 
leprosy infections. Although the 
absolute benefit is not large, it is 
significant from a public health 
perspective. There are no data 
on adverse events, but they are 
likely to be minor, given the 
nature of the intervention (single 
dose rifampicin). Therefore, 
the balance of effects probably 
favours the intervention.
There is efficacy, though limited 
in time, and the intervention is 
also likely to improve early case 
detection among contacts.
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Judgement Research evidence Additional consideration
Re
so
ur
ce
s 
re
qu
ire
d
How large are 
the resource 
requirements (costs)?
  Large costs
  Moderate costs
  Negligible costs 
and savings
  Moderate savings
  Large savings
  Varies
  Don't know
No research evidence was 
identified. Although the costs of 
the intervention (SDR) are likely 
to be low where contact screening 
occurs, there are additional costs 
related to contact tracing and 
follow-up that are more difficult 
to estimate.
Costs probably not negligible 
especial ly in high-burden 
countries.
C
er
ta
in
ty
 o
f e
vi
de
nc
e 
of
 
re
qu
ire
d 
re
so
ur
ce
s
What is the 
certainty of the 
evidence of resource 
requirements (costs)?
  Very low
  Low
  Moderate
  High
  No included 
studies
No research evidence was 
identified.
See above.
C
os
t–
ef
fe
ct
iv
en
es
s
Does the cost–
effectiveness of the 
intervention favour 
the intervention or 
the comparison?
  Favours the 
comparison
  Probably favours 
the comparison
  Does not favour 
either the 
intervention or the 
comparison
  Probably favors 
the intervention
  Favours the 
intervention
  Varies
  No included 
studies
A cost–effectiveness analysis of 
the RCT carried out in Bangladesh 
found an incremental cost–
effectiveness ratio of < US$ 200 
per case of leprosy averted. Costs 
may vary in other countries and 
indirect costs were not measured.
Hard to estimate with limited 
evidence. Probably not very 
high given the limited in time 
efficacy.
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Judgement Research evidence Additional consideration
Eq
ui
ty
What would be the 
impact on health 
equity?
  Reduced
  Probably reduced
  Probably no 
impact
  Probably increased
  Increased
  Varies
  Don't know
Preventive treatment might 
improve heal th equi ty  by 
preventing future cases of leprosy 
but could worsen health equity 
due to stigma or other social 
effects.
If rifampicin were to be self-
purchased by the patient, 
the costs would probably be 
affordable. 
Reduced occurrence of the 
d i sease  would  represent 
a benefit for contacts that 
constitute the high-risk group.
Ac
ce
pt
ab
ili
ty
Is the intervention 
acceptable to key 
stakeholders?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
One qualitative study found 
that people found preventive 
treatment to be acceptable.
One qualitative study found 
that people found preventive 
treatment to be acceptable.
Fe
as
ib
ili
ty
Is the intervention 
feasible to 
implement?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
No research evidence was 
identified. Providing SDR is 
probably feasible but contact 
tracing may be more difficult to 
implement.
Preliminary reports for LPEP 
show feasibility under pilot-
study conditions.
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Summary of judgements
Judgement Implications
Problem No Probably no Probably yes Yes Varies Don't know
Desirable 
effects
Trivial Small Moderate Large Varies Don't know
Undesirable 
effects
Large Moderate Small Trivial Varies Don't know
Certainty of 
evidence
Very low Low Moderate High No included 
studies
Values Important 
uncertainty 
or variability
Possibly 
important 
uncertainty 
or variability
Probably no 
important 
uncertainty 
or variability
No 
important 
uncertainty 
or variability
No known 
undesirable 
outcomes
Balance of 
effects
Favours the 
comparison
Probably 
favours the 
comparison
Does not 
favour either 
intervention 
or 
comparison
Probably 
favours the 
intervention
Favours the 
intervention
Varies Don’t know
Resources 
required
Large costs Moderate 
costs
Negligible 
costs and 
savings
Moderate 
savings
Large savings Varies Don't know
Certainty 
of evidence 
of required 
resources
Very low Low Moderate High No included 
studies
Cost–
effectiveness
Favours the 
comparison
Probably 
favours the 
comparison
Does not 
favour either 
intervention 
or 
comparison
Probably 
favours the 
intervention
Favours the 
intervention
Varies No included 
studies
Equity Reduced Probably 
reduced
Probably no 
impact
Probably 
increased
Increased Varies Don't know
Acceptability No Probably no Probably yes Yes Varies Don't know
Feasibility No Probably no Probably yes Yes Varies Don't know
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Conclusion: Is there an effective and safe chemoprophylaxis regimen for prevention 
of leprosy among contacts of leprosy patients and for high-risk populations that could 
be used under programmatic conditions?
Type of 
recommendation
Strong 
recommendation 
against the 
intervention
Conditional 
recommendation 
against the 
intervention
Conditional 
recommendation 
for either the 
intervention or 
the comparison
Conditional 
recommendation 
for the 
intervention
Strong 
recommendation 
for the 
intervention
Recommendation The GDG recommends the use of SDR as preventive treatment for contacts of leprosy 
patients, in adults and children 2 years of age and above, after excluding leprosy and TB 
disease and other contraindications, by programmes that can ensure adequate management 
of contacts and upon agreement of the index case to disclose his/her disease.
Justification Moderate efficacy demonstrated by a single double-blind RCT. For every 1000 contacts 
treated with SDR, it is estimated that four cases of leprosy would be prevented at 1–2 
years and three cases prevented at 5–6 years. The provision of chemoprophylaxis is likely 
to improve contact screening and preliminary reports suggest feasibility and acceptability 
under programmatic conditions. One study showed that the intervention was cost effective.
Subgroup 
considerations
None.
Implementation 
considerations
Good coverage of contact screening is essential. Detailed guidelines will be necessary to 
ensure confidentiality considering stigma, discrimination and contextual sensitivity and the 
delivery of appropriate health education to patients and contacts. The recommendation is 
conditional upon the ability of programmes to be able to adequately identify and manage 
contacts of leprosy patients.
Monitoring and 
evaluation
There will be a need for additional adverse events monitoring, and monitoring of effects 
related to stigma.
Research 
priorities
Studies that evaluate the effectiveness of alternative regimens (different drugs and different 
durations of treatment) are encouraged as well as studies that investigate the efficacy of 
chemoprophylaxis provided through a “blanket/high-risk population” approach, since such 
an approach might show more effectiveness, increase feasibility, and may result in less 
risk of stigma. Studies are also needed of the possible effect of repeating administration 
of SDR in contacts every 2 years.
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Question 3b: Is there an effective vaccine for the prevention of leprosy 
that could be used under programmatic conditions, with or without 
chemoprophylaxis, for contacts of leprosy patients and also among the 
general population?
Population: Adults and children in general 
population
Adults and children contacts of 
patients with leprosy
Background:
Despite known evidence of the efficacy of BCG 
to prevent leprosy, no WHO recommendations 
have been released for its use as a preventive tool 
against leprosy. Several studies especially from 
high-burden countries assessed the efficacy 
of other vaccines and of the combination of 
post-exposure prophylaxis with BCG at birth 
and/or with BCG revaccination.
Intervention: BCG
BCG revaccination
BCG + SDR
BCG + M. leprae
Other vaccines (ICRC, 
M. indicum pranii)
Comparison: No intervention (no vaccination)
Main outcomes: Occurrence of leprosy disease
Setting: All settings
Perspective: Clinic/field
Assessment
Judgement Research evidence Additional consideration
Pr
ob
le
m
Is the problem 
a priority?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
Leprosy is a preventable infectious disease 
with important clinical, social and public 
health consequences. Vaccines are a core 
intervention to prevent and effectively 
bring down the burden of communicable 
diseases and their impact on the health of 
the population.
With only partial efficacy of a 
chemoprophylaxis regimen, 
the availability of a vaccine 
becomes an important tool.
D
es
ir
ab
le
 e
ff
ec
ts
How 
substantial are 
the desirable 
anticipated 
effects?
  Trivial
  Small
  Moderate
  Large
  Varies
  Don't know
Desirable anticipated effects:
Evidence indicates that several vaccination 
interventions are effective at reducing the 
risk of leprosy.
The GDG considered that 
immunoprophylaxis could 
be important in leprosy.
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Judgement Research evidence Additional consideration
U
nd
es
ir
ab
le
 e
ff
ec
ts
How 
substantial are 
the undesirable 
anticipated 
effects?
  Large
  Moderate
  Small
  Trivial
  Varies
  Don't know
Undesirable anticipated effects:
Data on adverse events of vaccinations 
are limited.
Summary of findings:
Effects of vaccination on risk of leprosy.
One RCT found effects of SDR greater in 
persons who also received childhood BCG 
(quality: low)
• Placebo: OR 1 (reference)
• SDR and childhood BCG: OR 0.20 
(0.08–0.49)
• Childhood BCG alone: OR 0.43 (0.25–
0.75)
• SDR alone: OR 0.42 (0.26–0.69)
Comparison Findings Quality
BCG at birth 
vs no BCG or 
placebo
Pooled OR 0.45 
(0.34–0.56) from 
SR and 0.43 
(0.25–0.75) from 
additional RCT
Moderate*
BCG at birth 
plus killed 
M. leprae vs 
placebo
RRR 64% (50–74%) Low^
BCG plus killed 
M. leprae vs 
BCG alone
RR 1.06 (0.62 to 
1.82), RR 0.89 
(95% CI 0.53 to 
1.47), and RR 0.55 
(CI not available)
Low*
BCG 
revaccination in 
contacts vs no 
BCG
RR 0.51 (0.26–
0.99), RR 0.99 
(0.69–1.43),
Low+
ICRC vaccine vs 
placebo
RRR 66% (48–77%) Low^
M.indicum pranii 
vs placebo
OR 0.61 (0.46–
0.80) and RRR 26% 
(1.9–44%)
Moderate~
*Downgraded one level due to inconsistency
^Downgraded two levels due to moderate risk of bias 
and inability to assess consistency (estimate based on 
1 study)
+Downgraded two levels due to moderate risk of bias 
and inconsistency
~Downgraded one level due to moderate risk of bias
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Judgement Research evidence Additional consideration
C
er
ta
in
ty
 o
f e
vi
de
nc
e
What is 
the overall 
certainty of the 
evidence of 
effects?
  Very low
  Low
  Moderate
  High
  No included 
studies
Evidence for some vaccine intervention 
is moderate. Data on adverse events is 
limited but they are likely to be few for 
BCG based on experience on its use in 
tuberculosis prevention.
Ba
la
nc
e 
of
 e
ff
ec
ts
Does the 
balance 
between 
desirable and 
undesirable 
effects 
favour the 
intervention 
or the 
comparison?
  Favours the 
comparison
  Probably 
favours the 
comparison
  Does not 
favour 
either the 
intervention 
or the 
comparison
  Probably 
favours the 
intervention
  Favours the 
intervention
  Varies
  Don't know
Strongest evidence is for BCG at birth. 
Evidence is limited for other vaccination 
interventions but suggests benefit of BCG 
at birth plus killed M. leprae, ICRC vaccine, 
and M. indicum pranii. BCG + rifampicin 
more effective than either intervention 
alone in contacts in one sub-study from 
the RCT.
Evidence on adverse events is limited.
For other vaccines and 
revaccination there is limited 
evidence.
No appraisal of evidence on 
adverse events.
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Judgement Research evidence Additional consideration
Re
so
ur
ce
s 
re
qu
ir
ed
How large are 
the resource 
requirements 
(costs)?
  Large costs
  Moderate 
costs
  Negligible 
costs and 
savings
  Moderate 
savings
  Large savings
  Varies
  Don't know
No research evidence was identified. Costs 
of BCG at birth are likely to be mainly 
related to the cost of the vaccine; costs of 
vaccination of contacts will include costs 
of contact tracing.
C
er
ta
in
ty
 o
f e
vi
de
nc
e 
of
 r
eq
ui
re
d 
re
so
ur
ce
s
What is the 
certainty of 
the evidence 
of resource 
requirements 
(costs)?
  Very low
  Low
  Moderate
  High
  No included 
studies
No research evidence was identified.
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Judgement Research evidence Additional consideration
C
os
t–
ef
fe
ct
iv
en
es
s
Does the cost–
effectiveness 
of the 
intervention 
favour the 
intervention 
or the 
comparison?
  Favours the 
comparison
  Probably 
favours the 
comparison
  Does not 
favour 
either the 
intervention 
or the 
comparison
  Probably 
favours the 
intervention
  Favours the 
intervention
  Varies
  No included 
studies
No research evidence was identified.
Eq
ui
ty
What would be 
the impact on 
health equity?
  Reduced
  Probably 
reduced
  Probably no 
impact
  Probably 
increased
  Increased
  Varies
  Don't know
Universal vaccination at birth likely to 
improve health equity by preventing 
leprosy and not focusing prevention on 
contacts, which may result in stigma.
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Judgement Research evidence Additional consideration
Ac
ce
pt
ab
ili
ty
Is the 
intervention 
acceptable 
to key 
stakeholders?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
No research evidence was identified. 
However, in some settings vaccination 
programmes are already performed and 
appear acceptable.
Programmes might  be 
reluctant to implement due 
to potential costs.
Fe
as
ib
ili
ty
Is the 
intervention 
feasible to 
implement?
  No
  Probably no
  Probably yes
  Yes
  Varies
  Don't know
No research evidence was identified. 
However, BCG at birth is already routine 
in most high leprosy endemic countries 
and vaccination of contacts is performed 
in some settings.
For other vaccines uncertain 
– not current practice in the 
field.
Summary of judgements
Judgement Implications
Problem No Probably 
no
Probably 
yes
Yes Varies Don't know
Desirable 
effects
Trivial Small Moderate Large Varies Don't know
Undesirable 
Effects
Large Moderate Small Trivial Varies Don't know
Certainty of 
evidence
Very low Low Moderate High No included 
studies
Values Important 
uncertainty 
or variability
Possibly 
important 
uncertainty 
or 
variability
Probably 
no 
important 
uncertainty 
or 
variability
No 
important 
uncertainty 
or 
variability
No known 
undesirable 
outcomes
Balance of 
effects
Favours the 
comparison
Probably 
favours the 
comparison
Does not 
favour 
either 
intervention 
or 
comparison
Probably 
favours the 
intervention
Favours the 
intervention
Varies Don't know
Resources 
required
Large costs
Moderate 
costs
Negligible 
costs and 
savings
Moderate 
savings
Large 
savings
Varies Don't know
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Judgement Implications
Certainty 
of evidence 
of required 
resources
Very low Low Moderate High No included 
studies
Cost–
effectiveness
Favours the 
comparison
Probably 
favours the 
comparison
Does not 
favour 
either 
intervention 
or 
comparison
Probably 
favours the 
intervention
Favours the 
intervention Varies
No included 
studies
Equity Reduced Probably 
reduced
Probably 
no impact
Probably 
increased
Increased Varies Don't know
Acceptability No Probably 
no
Probably 
yes
Yes Varies Don't know
Feasibility No Probably 
no
Probably 
yes
Yes Varies Don't know
Conclusion: Is there an effective and safe tool for prevention of leprosy that could 
be used under programmatic conditions in the form of immunoprophylaxis, with 
or without chemoprophylaxis, for contacts of leprosy patients and also among the 
general population?
Type of 
recommendation
Strong 
recommendation 
against the 
intervention
Conditional 
recommendation 
against the 
intervention
Conditional 
recommendation 
for either the 
intervention or 
the comparison
Conditional 
recommendation 
for the 
intervention
Strong 
recommendation 
for the 
intervention
Recommendation The GDG brings to the attention of SAGE the following considerations:
• BCG at birth is effective in reducing the risk of leprosy disease and therefore its use 
should be maintained at least in all leprosy high-burden countries.
• The GDG points out the efficacy of the following vaccine, still in production, in 
preventing leprosy, according to RCTs:
 – M. indicum pranii
• Presently, there is insufficient evidence of the efficacy of BCG revaccination among 
contacts to recommend its use.
Justification Evidence suggests the efficacy of BCG and other vaccines to prevent leprosy.
BCG is easily accessible and already part of the vaccination policy of most endemic 
countries.
Other vaccines show similar or slightly lower efficacy compared to BCG.
Subgroup 
considerations
None.
Implementation 
considerations
Implementation considerations for BCG at birth are similar to other vaccinations given 
at birth (already routinely administered in most high-endemic countries). Vaccination 
assumes the availability of BCG.
Monitoring and 
evaluation
There might be the need to implement a monitoring system for adverse events if other 
vaccines are used (BCG adverse events monitoring already part of the EPI).
Research 
priorities
Trials of new and existing vaccines, including studies of LepVax, a new subunit vaccine
Any novel TB vaccines should also be evaluated for leprosy and Buruli ulcer prevention 
and vice versa
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Annex 3: Guide for the focus group 
discussions to identify 
values and preferences of 
persons affected by leprosy
Focus group composition:
 • between 7 and 10 people
 • men and women
 • younger and older people
 • preferably persons affected with a relatively recent diagnosis (not more than 5–7 
years)
 • PB and MB past leprosy diagnosis
 • former patients with and without disabilities
 • rural and urban
Instructions for focus group discussion: reunite the group and discuss the questions one 
at the time. Let the discussion flow. At the end of the discussion of each topic ask the group 
to agree on a list of the most important problems and suggestions, rate their importance 
from 1 to 4 (with 1 being the most important). Please tick the name of your country and fill 
in the information on attendance.
Outcome of the focus group discussion
1.  Diagnosis
In your experience, what are the major problems that prevent people from obtaining an 
accurate diagnosis of leprosy?
1 2 3 4
What are your suggestions for the most important changes to improve diagnosis of leprosy?
1 2 3 4
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2.  Medical treatment/MDT
In your experience, what are the major problems that prevent people from starting and 
completing appropriate medical treatment/MDT for leprosy?
1 2 3 4
Did you notice during the discussion if the problems mentioned were different for people 
diagnosed with PB compared to those with MB leprosy? If yes, indicate here which problems 
have been raised by one of the two groups only.
What are your suggestions for the most important changes to improve access and completion 
of medical treatment/MDT?
1 2 3 4
Did you notice during the discussion if the suggestions or ideas were different for people 
diagnosed with PB compared to those with MB leprosy? If yes, indicate here which suggestions 
have been raised by one of the two groups only.
3.  Contact tracing and follow up for prevention of leprosy
After a person has been diagnosed with leprosy, services often seek to follow up with their 
family and friends for contact tracing and prevention. What are your concerns about this?
1 2 3 4
What could leprosy services do to reduce your concerns about contact tracing and follow up?
1 2 3 4
If there was a treatment that could probably help prevent leprosy, what should services do 
to offer that treatment more easily to family and friends?
1 2 3 4
Guidelines for the diagnosis, treatment and prevention of leprosy86
Remarks
Add any comments that could not be easily captured/summarized in the grid above:
Country:
 • Colombia
 • Ghana
 • India
 • Nepal
How many people participated?
 • Total number:
 • Number of men:
 • Number of women:
 • Number of children:
 • Number with previous PB disease:
 • Number with disabilities:
 • Number from urban areas:
 • Number of people who were diagnosed with leprosy more than 5 years ago:
Date and venue where the focus group discussion took place:
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Annex 4: GRADE tables and literature 
review report
The GRADE tables for each set of PICO questions and the report of the literature review can 
be accessed on the webpage of WHO’s Global Leprosy Programme.
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The Guidelines for the Diagnosis, Treatment and Prevention of Leprosy provide 
state-of-the-art knowledge and evidence on leprosy diagnosis, treatment and 
prevention based on a public health approach in endemic countries. The target 
audience of this document includes policy-makers in leprosy or infectious 
diseases in the ministries of health (especially but not limited to endemic 
countries), nongovernmental organizations, clinicians, pharmaceutical 
companies, donors and affected persons. These leprosy guidelines have been 
developed by strictly following WHO's GRADE approach wherein all available 
evidence published in English has been taken into consideration. Funding 
support was received from The Nippon Foundation. 
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